## Original Article Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma

Sang Hyun Seo<sup>1,2</sup>, Kyung Joo Cho<sup>1,2</sup>, Hye Jung Park<sup>2</sup>, Hyemi Kim<sup>3</sup>, Hye Won Lee<sup>2,4</sup>, Beom Kyung Kim<sup>2,4</sup>, Jun Yong Park<sup>2,4</sup>, Do Young Kim<sup>2,4</sup>, Sang Hoon Ahn<sup>2,4</sup>, Seung Up Kim<sup>2,4</sup>

<sup>1</sup>Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea; <sup>2</sup>Yonsei Liver Center, Severance Hospital, Seoul, Korea; <sup>3</sup>Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul, Korea; <sup>4</sup>Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

Received February 18, 2021; Accepted September 20, 2021; Epub October 15, 2021; Published October 30, 2021

Abstract: The expression of Dickkopf-1 (DKK1), a negative regulator of the Wnt/β-catenin signaling pathway, is upregulated in hepatocellular carcinoma (HCC). Here, we investigated the tumorigenic and angiogenic potential of DKK1 in HCC. Stable cell lines were established using the clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9)-based DKK1 knock-out system in Hep3B cells and the tetracyclinebased DKK1 inducible system in Huh7 cells. Multicellular tumor spheroids (MCTSs) were cultured using Hep3B stable cells. We also employed xenografts generated using Hep3B stable cells and transgenic mouse models established using hydrodynamic tail vein injection. The angiogenic potential increased in HUVECs treated with CM from Huh7 stable cells with high DKK1 expression and Hep3B wild-type cells. DKK1 accelerated the downstream molecules of vascular endothelial growth factor receptor 2 (VEGFR2)-mediated mTOR/p70 S6 kinase (p70S6K) signaling. MCTSs generated using Hep3B wild-type cells promoted compact spheroid formation and increased the expression of CD31 and epithelial-mesenchymal transition (EMT) markers, and increased the VEGFR2-mediated mTOR/ p70S6K signaling, compared to the controls (all P<0.01). Xenograft tumors generated using Hep3B cells with DKK1 knock-out (n=10) exhibited slower growth than, the controls (n=10) and the expression of Ki-67, VEGFR2, CD31 and EMT markers decreased (all P<0.05). In addition, forced DKK1 expression with HRAS in transgenic mouse livers (n=5) resulted in the formation of more tumors and increased expression of downstream molecules of VEGFR2mediated mTOR/p70S6K signaling pathway as well as Ki67, CD31 and EMT markers (P<0.05), compared to that of the controls (n=5). Our findings indicate that DKK1 facilitates angiogenesis and tumorigenesis by upregulating VEGFR2-mediated mTOR/p70S6K signaling in HCC.

**Keywords:** Dickkopf-1, vascular endothelial growth factor receptor 2, hepatocellular carcinoma, angiogenesis, epithelial-mesenchymal transition

#### Introduction

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is derived from hepatocytes and occurs in more than approximately 80% of cases of liver cancer [1]. HCC is a hypervascular tumor in which angiogenesis plays an important role in development, invasion and metastasis [2]. Tumor growth relies on angiogenesis, the formation of new blood vessels from preexisting vasculature, to receive an adequate supply of oxygen and nutrients into the tumors [3, 4]. Accordingly, anti-HCC agents, such as sorafenib and lenvatinib, which target vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) receptors have shown survival benefits in HCC treatment [5].

Pro-angiogenic factors such as VEGF, FGF and PDGF are known to activate tyrosine kinases and subsequent downstream intracellular signaling through mitogen-activated protein kinase [6]. Both VEGF and VEGF receptors (VEGFRs), the most prominent and widely researched regulators of angiogenesis, are critical for HCC growth and development [7]. The binding of VEGF to VEGFR leads to endothelial proliferation and migration as well as formation and branching of new tumor blood vessels [8]. In addition, VEGFR1 activation upregulates the expression of epithelial-mesenchymal transition (EMT)-associated factors, such as Snail, Twist and Slug in HCC [9].

Dickkopf-1 (DKK1), which binds to the low-density lipoprotein receptor-related protein-5/6 Wht co-receptor, is a secreted protein that functions as a negative regulator of Wht signaling [10-15]. Wht signaling regulates diverse cellular and biological processes such as proliferation, survival, migration and liver development [16-18]. In addition, the DKK protein family has been found to regulate angiogenesis, and it has been reported that the Wht signaling pathway and DKK1 modulate tumorigenesis during vasculogenesis and angiogenesis [19].

Several studies have reported that DKK1 expression is upregulated in HCC cell lines [20-22] and the tumor tissues and serum samples of patients with HCC [20, 23, 24]. Ectopic DKK1 expression promotes HCC cell migration and invasion through  $\beta$ -catenin/matrix metalloproteinase (MMP7) signaling [25]. Moreover, the downregulation of DKK1 expression using siRNA has been shown to inhibit invasion and metastasis in HCCLM3 cells. In contrast, DKK1 overexpression in the HepG2 cell line has been shown to significantly promote its migration and invasiveness [26]. These results indicate that DKK1 regulation can be a promising target for angiogenesis in HCC.

In a previous study, we showed that DKK1 induces angiogenesis by regulating VEGF receptor 2 (VEGFR2) [27], but the correlation between DKK1 and angiogenesis in HCC remains poorly understood. In the present study, we investigated the angiogenic and tumorigenic role of DKK1 in HCC using diverse models of regulated DKK1 expression and found that DKK1 promotes angiogenesis by upregulating VEGFR2mediated mammalian target of rapamycin (mTOR)/p70 S6 kinase (p70S6K) signaling in HCC.

### Material and methods

### Cell lines

Huh7 (Korean Cell Line Bank, Seoul, Korea), GP2-293 (Clontech, California, USA), Hep3B,

LX2 [Dr. Seo [28]] and WI38 cells were cultured at 37°C with 5%  $CO_2$  in Dulbecco's Modified Eagle's Medium (Gibco, Carlsbad, CA, USA), Modified Eagle's Medium (Gibco) or RPMI-1640 (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1x penicillin-streptomycin (Welgene, Daegu, Korea). Human umbilical vein endothelial cells (HUVECs) were cultured in Medium 200 (Gibco) supplemented with low serum growth supplement (Gibco) at 37°C with 5%  $CO_2$ .

### Generation of stable cell lines

Stable cell lines were generated using the clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease 9 (CRISPR/Cas9)-based DKK1 knockout system in Hep3B cells and the tetracycline-based DKK1 inducible system in Huh7 cells. The Hep3B wild-type cells used in this study meant that Hep3B cells were untreated, and previous studies showed that Hep3B was originally isolated from a liver biopsy of an 8-year-old black man with primary HCC [29, 30]. Alt® CRISPR-Cas9 system, CRISPR RNA (crRNA): Guide RNA (gRNA) targeting the human DKK1 locus along with transactivating crRNA (tracrRNA), were obtained from Integrated DNA Technologies (San Diego, CA, USA) for Hep3B stable cell line. crRNA was used to select target region within the first exon of the human DKK1 gene. Tracr and crRNA were combined according to the manufacturer's protocol and then crRNA: tracrRNA duplexes were with Cas9 protein. Subsequently, the Alt® CRISPR-Cas9 system was transfected into Hep3B cells using Lipofectamine<sup>™</sup> RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA). Off-target effects in the two selected stable cell line clones were identified using whole genome sequencing (Promega, Madison, WA, USA) and the knock-out sequence of the human DKK1 exon-1 gene was confirmed by Sanger sequencing (Macrogen, Seoul, Korea).

GP2-293 was transfected to make regulator (Retro-X Tet-On Advanced Inducible Expression System and pVSV-G) and response (pRetroXtight Pur-DKK1/pVSV-G or pRetroX-tight Pur-Mock/pVSV-G) plasmid (Clontech, California, USA) using CalPhos Mammalian Transfection Kit (Clontech). The regulator plasmid was added to the culture medium of Huh7 cells. Transfected Huh7 cells were selected by on the basis of resistance to the antibiotic, G418 (Takara Bio Inc, Seoul, Korea), followed by the addition of the response plasmid to the culture medium of the selected Huh7 cells. Twenty-four hours after infection, the cells were subjected to puromycin (Takara Bio Inc) selection.

### Assessment of DKK1 using ELISA

The concentration of DKK1 in HCC cell lines was measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Subsequently, all the groups of supernatants were collected and DKK1 levels were assayed in them.

### Cell invasion, tube formation and wound healing assay

The invasiveness of HUVECs was assessed using a transwell chamber (Corning Costar, Cambridge, MA, USA). Next,  $3 \times 10^4$  HUVECs/ well were treated with VEGF or recombinant DKK1 (rDKK1) in each transwell chamber. Following incubation for 24 h, the invading cells were stained with hematoxylin and eosin (H&E). The total number of invaded cells on the lower side of the filter was determined using a light microscope (Olympus, Tokyo, Japan) at 40 × magnification. Invading cells on the lower membrane surface were measured by imageJ software.

Tube formation by HUVECs was measured using Matrigel<sup>®</sup> (Corning). A 48 well plate (BD Falcon<sup>®</sup>, Bedford, MA, USA) was coated with 150  $\mu$ L Matrigel<sup>®</sup> and seeded with HUVECs (3 × 10<sup>4</sup>/ well), followed by the addition of conditioned medium (CM) from Hep3B and Huh7 stable cell lines. The plates were incubated for 4 h, following which tube formation was observed under a light microscope.

Wound healing assays were performed by creating identical wound areas into the cell monolayer using culture-inserts (Ibidi GmbH, Munich, Germany). A 24 well plate was coated with 2% gelatin (BD Biosciences) and seeded with HUVECs ( $2 \times 10^4$ /well) on each side of the culture-insert. After attachment, the cells were treated with CM from the HCC stable cell line, followed by detachment of the culture-insert. The wound images were captured at 0 and 6 h using a light microscope.

### mRNA isolation and RT-PCR

For PCR, total RNA was extracted using TRIzol<sup>™</sup> reagent (Invitrogen, California, USA) and synthesis of first strand cDNA (Superscript<sup>™</sup> III First-Strand Synthesis System, Invitrogen) was performed according to the manufacturer's recommended protocols. A PCR master mix (Power SYBR<sup>™</sup> Green PCR Master Mix; Applied Biosystems, Warrington, UK) was used for quantitative PCR performed on the Step-OnePlus<sup>™</sup> PCR System (Applied Biosystems).

### Western blot analysis

Cells and tissues were washed and lysed with RIPA buffer containing a protease inhibitor cocktail (Thermo Fisher Scientific) and a phosphatase inhibitor cocktail (GenDEPOT, Katy, TX, USA). Cell and tumor lysates were cleared using centrifugation, separated using SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were incubated with antibodies against DKK1 (R&D Systems), VEGFR2, phosphorylated VEGFR2 (p-VEGFR2), mTOR, phospho-p70S6K, GAPDH, phosphoinositide 3-kinase (PI3K) and p-Akt [at Ser473] (Cell Signaling Technology, Danvers, MA, USA) at the recommended concentrations. The blots were developed using the enhanced chemiluminescence technique (PerkinElmer, Waltham, MA, USA) according to the manufacturer's instructions.

### Spheroid fabrication

Hep3B-only or hybrid spheroids were fabricated in a low attachment multiple well plate (Corning). To model tumor complexity and heterogeneity, we formed multicellular tumor spheroids (MCTSs) with Hep3B stable cell lines and stromal cells, such as HUVECs (human endothelial cells), LX2 (human hepatic stellate cells) and WI38 (human fibroblasts) and counted them prior to mixing them in the desired ratio. A 200 µL cell mixture of these four cell types was prepared in the following ratio: Hep3B stable cells: HUVECs: LX2: WI38=4: 2: 1: 1. This mixture was subsequently pipetted onto the plate. Images of MCTS were acquired using a microscope (Olympus) and imported into ImageJ software. The average radius (r) was then calculated using ImageJ software and used to obtain the volume value (V) with the following formula:  $V=4/3\pi r^3$ .

### Animals

All experiments involving live mice were performed according to the Guidelines and Regulations for the Care and Use of Laboratory Animals in AAALAC-accredited facilities, and were approved by the Animal Policy and Welfare Committee of the Yonsei University College of Medicine (Permit number: 2018-0088). We purchased 4-5-week-old C57BL/6 male mice from Orientbio (Seongnam, Korea), while 4-week-old BALB/c nude male mice were purchased from Central Lab. Animal Inc. (Seoul, Korea).

### Xenograft mouse model

The Hep3B stable cell line  $(5 \times 10^6 \text{ or } 7 \times 10^6 \text{ cells})$  in HBSS was mixed with Matrigel<sup>®</sup> [2:1] (Corning) and then inoculated subcutaneously into the left and right flanks of each BALB/c nude mouse. Tumors were monitored once a week and the tumor volume was calculated with the help of Vernier calipers. The volumes of the tumors were calculated using a standard formula (length × width<sup>2</sup> × 0.5) and growth curves were drawn. Nine weeks later, animals in all the groups were sacrificed, following which their tumors were harvested and fixed in 10% formalin.

### Histology analysis

The specimens embedded in paraffin blocks were sectioned into 4-µm slices. Specimens for histological analysis were processed using conventional H&E staining for the visualization of general tissue morphology. Stained specimens were inspected using a microscope (Olympus).

### Immunohistochemistry and immunofluorescence

Paraffin sections were deparaffinized in xylene and rehydrated through a gradual decrease in ethanol concentration. The antigen epitopes were then unmasked using sodium citrate buffer (pH=6.0). Subsequently, the sections were incubated overnight at 4°C using the following primary antibodies: anti-Ki-67 (Cell Signaling Technology), anti- anti-cluster of differentiation 31 (CD31) (Invitrogen), anti-HRAS (Santa Cruz Biotechnology, California, USA), anti-p-VEGFR2 (Cell signaling) and anti-p-Akt (Cell signaling). After primary incubation, the sections were incubated with the appropriate biotinylated secondary antibodies followed by treatment with freshly prepared 3,3'-diaminobenzidine substrates (Vector Laboratories, Burlingame, CA, USA). Sections were lightly counter-stained with hematoxylin and mounted. For immunofluorescence (IF), the sections were probed with anti-DKK1 (R&D systems), CD31 (Invitrogen), anti-VEGFR2, anti-vimentin, anti-fibronectin and anti-E-cadherin antibodies (Cell Signaling Technology). Next, after washing with phosphate-buffered saline, the sections were incubated with secondary antibodies, stained with 4',6-diamidino-2-phenylindole and then embedded Fluoromount-G<sup>™</sup> (Invitrogen). Fluorescence images were obtained using a Zeiss LSM 700 confocal microscope (Carl Zeiss, Oberkochen, Germany).

### Hydrodynamic tail-vein injection

The plasmids pT2/HRAS<sup>G12V</sup>, pT2/shp53, and PT2/C-Luc/PGK-SB13 were prepared using endotoxin-free EndoFree<sup>®</sup> Plasmid Maxi Kit (Qiagen, Hilden, Germany). DNA mixtures of transposons (pT2 plasmids) and transposaseencoding vector (pPGKSB13) were suspended in Lactated Ringer's solution and subsequently injected into the lateral tail veins of 5- to 6-week old male mice (0.1 mL/g body weight) in less than 7 s. The livers were harvested 5 weeks following the hydrodynamic transfection, unless specified otherwise.

### Statistical analysis

Statistical analyses were conducted using an unpaired parametric Student's t-test or Fisher's exact test, as appropriate. A value of P<0.05 was chosen to indicate statistical significance.

### Results

## Establishment and characterization of stable cell lines

Treatment with rDKK1 resulted in a concentration-dependent enhancement of the invasive potential of HUVECs (**Figure 1A**). Upon confirmation of the expression of DKK1 in various human HCC cell lines, it was found that the levels of secreted DKK1 were high in Hep3B cells, but low in Huh7, SNU475, and SNU449 cells (**Figure 1Ba**). Accordingly, Huh7 cells with low DKK1 expression and Hep3B cells with high DKK1 expression were selected for the regulation of DKK1 expression. Stable cell lines were established using the CRISPR-Cas9-based DKK1 knockout system in Hep3B cells and the



**Figure 1.** Regulation of DKK1 gene expression in Hep3B and Huh7 cells. A. Effects of DKK1 on invasion assay in HUVECs. NT: no treatment. HUVECs were treated with the indicated concentration of rDKK1 and 50 ng/mL VEGF (as a positive control). B. DKK1 expression levels of human hepatocellular carcinoma cell lines were measured using ELISA (a) and CRISPR-Cas9 based DKK1 knockout was confirmed by PCR (b). C. Western blot analysis of aggregated proteins, collected using centrifugation from Hep3B wild-type, Hep3B CRISPR#73 (#73) and Hep3B CRISPR#131 (#131) cells. DKK1-transfected HEK 293T cells were used as a positive control. D. Protein levels of secreted DKK1 from Hep3B wild type, #73 and #131 cells were measured using ELISA. E. Western blot analysis of aggregated proteins from Hep3B, Huh7, Huh7 Pur-DKK1, Huh7 Pur-Mock cells. Huh7 Pur-DKK1 and Huh7 Pur-Mock cells were cultured in the absence or presence of doxycycline (100 ng/mL) at 37 °C for 48 h. Hep3B cells were used as a positive control for DKK1. Lysate: the aggregated fraction after centrifugation; sup: the supernatant (soluble fraction). F. Secreted DKK1 protein levels of CM of Huh7 Pur-Mock and HuH7 Pur-DKK1 cells were measured using ELISA after incubation with doxycycline (100 ng/mL) for 24 h.

tetracycline-based DKK1 inducible system in Huh7 cells. We used the CRISPR-Cas9 system to select the target region within exon-1 of the human DKK1 gene (Figure 2A, 2B). Subsequently, several colony cell lines were established by transfection, and it was found that

the sizes of the DKK1 exon-1 in colonies 73 (Hep3B CRISPR#73 cells) and 131 (Hep3B CRISPR#131 cells) were smaller than those of the positive control (Hep3B wild-type cells) (Figure 1Bb, confirming DKK1 knock-out by sequencing Figure 3A, 3B). We also observed that the expression of DKK1 and the protein levels of secreted DKK1 in Hep3B CRISPR#73 cells were significantly lower than those in Hep3B wild-type and CRISPR#131 cells (all P<0.001) (Figure 1C and 1D). Consequently, Hep3B CRISPR#73 cells were used in this study because DKK1 protein levels in Hep3B CRISPR#73 cells were significantly lower than those in Hep3B CRISPR#131 cells. In addition, the expression of DKK1 and the protein levels of secreted DKK1 were significantly higher in doxycycline-treated pRetroX-tight Pur-DKK1 transfected Huh7 cells (Huh7 Pur-DKK1 cells) than in Huh7 wild-type cells and pRetroX-tight Pur-Mock transfected Huh7 cells (Huh7 Pur-Mock cells) (all P<0.001) (Figure 1E). In addition, we confirmed that the protein levels of secreted DKK1 in CM were higher in Huh7 Pur-DKK1 cells than in Huh7 Pur-Mock cells, when the Huh7 stable cells were treated with doxycycline for 24 h (Figure 1F).

# DKK1 enhances the angiogenic potential of HUVECs

We investigated whether DKK1 regulates endothelial cell tube formation and migration, which are two important features of angiogenesis [31]. Tube formation was enhanced in HUVECs treated with concentrated CM from doxycycline-treated in Huh7 Pur-DKK1 cells, whereas it was not enhanced in HUVECs treated with concentrated CM from Hep3B CRISPR#73 cells, compared to the controls (Figure 4A). In addition, HUVECs treated with CM from doxycycline-treated in Huh7 Pur-DKK1 and Hep3B wild-type displayed higher migration ability than the controls (Figure 4Ba). In addition, HUVECs treated with CM from Hep3B CRISPR#73 and #131 cells showed lower migration ability compared to growth medium and CM from Hep3B wild type (P<0.001). Whereas HUVECs treated with CM from CRISPR#73 and CRISPR#131 displayed no differences (Figure 4Bb). The effects of VEGFR2 downstream signaling were examined to understand the mechanism underlying DKK1 induced angiogenesis in HUVECs. We found that DKK1 increased the expression of p-VEGFR2. In addition, DKK1 significantly enhanced the expression of VEGFR2, p110 $\alpha$ , p-Akt, p-mTOR and p-p70S6K in HUVECs (all P<0.001) (Figure 4C). Moreover, we demonstrated that HUVECs treated with rDKK1 showed increased Ki67 expression, compared to untreated HUVECs (P<0.01) (Figure 4D). In addition, rDKK1 treatment significantly increased VEGFR2-mediated Akt/mTOR/p70S6K signaling, whereas these protein levels were decreased by the VEGFR2-mediated Akt/ mTOR/p70S6K signaling inhibitor, quercetin treatment compared to the control (all P<0.001). However, rDKK1 combined with quercetin treatment ameliorated VEGFR2mediated Akt/mTOR/p70S6K signaling compared to rDKK1 treatment alone (P<0.001) (Figure 4E). Moreover, guercetin treatment showed no differences in the migration ability of HUVECs, whereas rDKK1 treatment significantly increased it, compared to controls (all P<0.01). However, rDKK1 combined with Quercetin treatment ameliorated the migration ability of HUVECs, compared to rDKK1 treatment (P<0.05) (Figure 4F). These data demonstrate that DKK1 might enhance the angiogenic potential and proliferation of HUVECs through VEGFR2-mediated mTOR/p70S6K signaling in vitro.

## Co-culture with Hep3B stable cells and stromal cells

To investigate whether DKK1 induces angiogenesis in HCC spheroids, we generated an MCTS. We confirmed a profound enhancement of spheroid compactness in MCTS generated using Hep3B wild-type cells, compared to the control (Figure 5A). IF staining of MCTS showed that DKK1 expression levels in MCTS generated using Hep3B wild-type cells were significantly higher than in those generated using Hep3B CRISPR#73 cells (Figure 5B). Expression of the endothelial cell marker, CD31, was enhanced in MCTS generated using Hep3B wild-type, compared to the control. In addition, expression levels of the mesenchymal cell markers, vimentin and Slug, were increased (all P<0.01), whereas expression of the epithelial cell marker, E-cadherin, was attenuated (P<0.001) in MCTS generated using Hep3B wild-type cells, compared to MCTS generated using Hep3B CRISPR#73 cells (Figure 5C). In addition, MCTS generated using Hep3B wildtype cells increased the expression of VEGFR2mediated mTOR/p70S6K signaling downstream proteins, compared to that generated using Hep3B CRISPR#73 (Figure 5D).

А	TATGACTTGTGTGCACAGTCAGCGAGTATTGGCATAAAGGAGGGGCAAAAAGTGCTTTTGCAGAGGCCTATCACCCCTCGGCTCTGTAAAGTATTTCAGATCCCGGATAATTCAACCCTTACTGCCAGGGCACCCAAGTTCCCCGGGGCAAAAAGTGCTTTTGCAGAGCCCTATCACGCCTGCTGCTGCCGCCTGCTACTAGTCCCGGATAATTCAACCCTTACTGCCAGGGCACCCAAGTTCCCGGGGGGGCAAAAAGTGCTTTTGCAGAGCCCTATCACGTCCGGGCAAAGTGCCTGCTGCGCGCCGCGCAAGTTCCCGGCAAGTGCCCGGCAAGTGCCCGGCAAGTGCCCGGCAAGTGCCTGCGCGCCGCGCAGGCCCTGCAAGTTCCGGGCACCCGAGTTCCGGGGGGGCCCCAAGTTCCCGGGGGGGG	680
	ATACTGAACACCGTGTCACGCCCATATACGGTACCGTATTTCCCCGTATTTCCCCGGTTTTCCCGGAAACGGTCCGGGGGGGG	
	Forward Y D L C A Q S A S I G I K E R G K K C F C R A Y H P S A L . S I S D P D N S T L T A R Q G H P S S Q S S C C R L H M T C V H S Q R V L A . R R G A K S A F A E P I T P R L C K V F Q I R I I Q P L L P G K G T Q V P R V P A A A C I . L V C T V S E Y W H K G E G Q K V L L Q S L S P L G S V K Y F R S G . F N P Y C Q A R A P K F P E F L L P P A	
	$ \begin{array}{c} TTATTAAAGTCGTCGTCTGCTATAACGCTCGCTGGTAGCCTTCACCCCGAAGGTGAAGGCGGCGAGCGA$	850
		1020
	S R L C C L P P K G P E C S G P A V . R Q P R W R W R R R A L C S L Q S G L W D R R G L P D P D S A A E P A R F R P G F V V S L P R G R N A P G P R Y K G S R G G G G G A E L C A P C S Q D S G T A G G S R T L T L Q P N R H G F V P A L L S P S Q G A G M L R A R G I K A A A V A V A A Q S S V L P A V R T L G P Q G A P G P . L C S R T G T V S	
		1190
	Disk 1 - sent	
	G D P G L Q S D G H F L F L S P S . V L L R . W L W A Q R E L P G S L S R W . R R L S A A T L C W E . A P P . T R G T Q A C K V T V I F S F F L P L E S F . D D G S G R S G S Y P G L C R D G S G G S R R P P S A G S E R H L E L W G P R L A K . R S F S L S F S L L S P S E M M A L G A A G A T R V F V A M V A A A L G G H P L L G V S A T L N S	
	GTTCTCAATTCCAACGCTATCAAGAACCTGCCCCCACCGCTGCGGGGGCGCCGCGGGGCACCCAGGCCTGGGGGCCGGGGGAATCCTGTACCCGGGGGGGAATAAGTACCAGACCATTGACAACTACCAGGGGGGGG	1360
	CKK1 exent	
В	Forward : TGCACAGTCAGCGAGTATTG	

## Reverse : CTGGTAGTTGTCAATGGTCTGG

Figure 2. Generation of *DKK1* knock-out alleles using CRISPR/Cas9. A. Targeting strategy of the DKK1 exon-1 gene. Blue: primer binding site, Green: sequence of DKK1 exon-1, Yellow: single-guide RNA binding site. B. Sequence of PCR primers for DKK1 exon-1.

Α		₩570	v580	v590	<b>v€</b> 00	v610	v620	v630	v640 ·	v650 v	660 v	670	v680	₩690	₩700	w710	₩720
	Human DKK1	ANGTGCTTTTGCA	GAGCCTATCAC	CCCTCGGCTCT	<b>TAAAGTATTT</b>	CAGATCCGGA	тааттсаассо	TTACTGCCAGG	CYYREECYCC	CANGTTCCCAG	AGTTCCTGCT	eccecciec	λΤΤΤΛΤΤΛΛ	AGTCGTCTGC	TATAACGCTC	GCTGGTAGCO	TTC
	061129-BA-014-1-73-DKK1-F	ANGTGCTTTTGCA	GAGCCTATCAC	CCCTCGGCTCT	STAAAGTATTT	CAGATCCGGA	TAATTCAACCO	TTACTGCCAGG	CAAGGGCACC	CAAGTTCCCAG	AGITCCIGCI	eccecciec	λΤΤΤΑΤΤΑΑ	AGTCGTCTGC	TATAACGCTC	GCTGGTAGCO	TTC
		~20	~30	~40	~50	~60	~70	~80	~90	~100	~110	~120	~130	~140	~150	~160	~170
		∀730	₩740	⊽750	\$7€0	₩770	v780	v790	v800 ·	v810 v	820 v	830	v840	v850	<b>v8€</b> 0	v870	¥880
	Human DKK1	ACCCCGAAGGTGA	ecceeeccyec	CGAGCGACTAA	<b>SCARGGGAGGG</b>	GCGGGGGTGAA	GAGTGTCAAAG	GCCCCCCTTCA	TGTACACAAA	CACACCCCCTC	CCAGCCCCTC	CCAGCGCTI	TGAAATCCC	ATCCCCGGCTT	TGIIGICICC	CTCCCAAGGO	FGCC
	061129-BA-014-1-73-DKK1-F	ACCCCGAAGGTGA	ecceeeccyee	CGAGCGACTAA	SCARGGERGGG	GCGGGGGTGAA	GAGTGTCAAAG	GCCCCCCTTCA	TGTACACAAA	CACACCCCCTC	CCAGCCCCTC	CCAGCGCTT	TGAAATCCC	ATCCCCGGCTT	TGITGICICC	CTCCCAAGGO	FGCC
		~180	~190	~200	~210	~220	~230	-240	~250	~260	~270	-280	~290	-300	~310	~320	-330
		v890	v900	v910	₩920	4930	∀940	v950	v960 ·	v970 v	980 7	990	v1000	v1010	v1020	v1030	v1040
	Human DKK1	GGAATGCTCCGGG	CCCGCGGGTATA	AAGGCAGCCGCG	GIGGCGGIGG	CGGCGCAGAG	CICIGIGCICC	CTGCAGTCAGG	ACTCTGGGAC	CGCAGGGGGGCT	CCCGGACCCT	GACICIGCA	GCCGAACCG	GCACGGTTTC	GIGGGGACCO	AGGCTTGCA	LAGT
	061129-BA-014-1-73-DKK1-F	GGAATGCTCCGGG	CCCGCGGGTATA	AAGGCAGCCGCG	FOIGGCGGIGG	COGCGCAGAG	crererected	CTGCAGTCAGG	ACTCTGGGAC	COCAGGGGGGCT	CCCGGACCCT	GACTCTGCA	GCCGAACCG	GCACGGTITC	GTGGGGGACCC	AGGCTTGCAJ	LAGT
		~340	~350	-360	~370	~380	~390	~400	~410	~420	~430	~440	~450	~460	~470	~480	~490
		v1050	₹10€0	v1070	v1080	v1090	v1100	v1110	v1120 ·	v1130 v	1140 v	1150	v1160	v1170	v1180	v1190	₹1200
	Ruman DEE1	GACGGTCATTTTC	Territeriter	CCCTCTTGAGT	CULCULCUL	GATGGCTCTG	GCCCCACCGC	AGCTACCCGGG	ICITIGICGC	GATGGTAGCGG	CGGCTCTCGG	Ceeccyccc	TCTGCTGGG	AGTGAGCGCC	ACCITGAACI	CGGTTCTCA	ATTC
								1111									
	061129-BA-014-1-73-DKK1-F	GACGGTCATTTTC	Terretter	CCCTCTTGAGTO	CTTCTGAGAT	GATGGCTCTG	GGCGCAGCGGG	AGCT		GGTAGCGG	CGGCTCTCGG	CEECCACCC	TCTGCTGGG	AGTGAGCGCC	ACCITGAACI	CGGTTCTCA	ATTC
		^500	~510	~520	~530	~540	~550	~5€0			^\$70	~580	~590	~€00	~610	~620	~630
		v1210	v1220	v1230	v1240	v1250	v12€0	v1270	v1280 ·	v1290 v	1300 v	1310	v1320				
	Human DKK1	CAACGCTATCAAG	AACCTGCCCCC	ACCECTEEECE	SCECTECEEEG	CACCCAGGCT	CTGCAGTCAG	000000000000000000000000000000000000000	ANTCCTGTAC	CCCCCCCCCCC	TAAGTACCAG	ACCATTGAC	AACT				
	10000000000000000000000000000000000000												1111				
	061129-BA-014-1-73-DKK1-F	CAACGCTATCAAG	AACCTGCCCCC	ACCECTEEECE	SCECTECEEEG	CACCCAGGCT	CIECYELCYEL	000000000000000000000000000000000000000	AATCCTGTAC	CCCCCCCCCCCC	TAAGTACCAG	ACCATGAAA	AACT				
		^640	^650	^660	^€70	^€80	^690	^700	^710	^720	^730	2740	^750				
B		v550 v	-560 v	570	0 759	0 7600	o <del>√6</del> 10	¥620	₩620	7640	¥650	¥660	<b>∀€7</b> 0	v680	v690	700	,
В	Numan DEE1	v550 v	SEO VI	570 v58	0 v590	0 v600	0 v610	v620	v630	v640	v650	VÉÉO	v670	v680	v690	v700	CECTC
В	Human DKK1	VSSO CONCERNING	7560 vi	570 v58 IGCAGAGCCTAT	0 v590 CACCCCTCGG	0 v600 CTCTGTAAAGT	0 v610 FATTTCAGATC	v620 CGGATAATTCA	v630 ACCCTTACTGC	v640 CAGGCAAGGG	v650 CACCCAAGTT	v660 CCCAGAGIT	v€70 CCTGCTGCC	v680 GCCTGCATTT	v690 ATTAAAGTCG	⊽700 ГСТGСТАТАЯ	CGCTC
В	Human DKK1 062074-BA-024-1-121-DKK1-F	v550 v GGAGAGGGGCAJ	AAAGTGCTTT	570 v58 IGCAGAGCCTAT	0 v590 CACCCCTC660	0 v600 CTCTGTAAAGT	0 v610 TATTTCAGATC	v620 CGGATAATTCA	v620 ACCCTTACTGC	v640 CCAGGCAAGGGG	v650 CACCCAAGTT	vééo CCCAGAGTT	v670 CCTGCTGCC	v680 GCCTGCATTT	vé90 ATTAAAGTCG	v700 ICTGCTATAA	
В	Human DKK1 062074-BA-024-1-131-DKK1-5	V550 C	7560 v AAAAGTGCTTT IIIIIIIII ATAGTGCTTT 0 ^20	570 v58 IGCAGAGCCTAT IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	0 v59 CACCCCTCGGG IIIIIII CACCCCTCGGG ^40	0 v600 CTCTGTAAAGT IIIIIIIII CTCTGTAAAGT ^50	0 v610 TATTTCAGATC TATTTCAGATC C60	v620 CGGATAATTCA CGGATAATTCA CGGATAATTCA	v630 ACCCTTACTGC	v640 CCAGGCAAGGG CCAGGCAAGGG ^90	v650 CACCCAAGTT CACCCAAGTT CACCCAAGTT	véé0 CCCAGAGTT CCCAGAGTT CCCAGAGTT	v670 CCTGCTGCCC CCTGCTGCCC ^120	v680 GCCTGCATTT GCCTGCATTT GCCTGCATTT ^120	v690 ATTAAAGTCG IIIIIIII ATTAAAGTCG ^140	v700 TCTGCTATAA TCTGCTATAA ^150	) ICGCTC       ICGCTC ^160
В	Human DKK1 062074-BA-024-1-131-DKK1-5	v550 v GGAGAGGGGCAA I I II GAAAGACGGGCT 10 2710 11	7560 vi AAAAGTGCTTT: IIIIIIII ATAGTGCTTT: 0 ^20	570 v58 IGCAGAGCCTAT IIIIIIIIII IGCAGAGCCTAT ^20 720 v74	0 v59 CACCCCTCGGG CACCCCTCGGG ^40 0 v75(	0 v600 CTCTGTAAAGT CTCTGTAAAGT ^50 0 v760	0 v610 TATTTCAGATC IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	v620 CGGATAATTCA CGGATAATTCA CGGATAATTCA ^70 v780	v630 ACCCTTACTGC 111111111 ACCCTTACTGC ^80 v790	v640 CCAGGCAAGGGG CCAGGCAAGGGG ^90 v800	v650 CACCCAAGTT CACCCAAGTT ^100 v810	v660 CCCAGAGTT CCCAGAGTT ^110 v820	v670 CCTGCTGCCG CCTGCTGCCG ^120 v820	v680 GCCTGCATTT. GCCTGCATTT. ^130 v840	v690 ATTAAAGTCG IIIIIIII ATTAAAGTCG ^140 v850	₹700 ПСТБСТАТАА ПСТБСТАТАА ПСТБСТАТАА ^150 ₹860	) LCSCTC 11111 LCSCTC ^1€0
В	Human DKK1 062074-BA-024-1-131-DKK1-2 Human DKK1	v550 v 66A6A66666CA3 1 1 11 6AAA6AC6666CT 11 v710 v 6CT66TA6CCT	7560 vi AAAAGTGCTTTT I IIIIIII ATAGTGCTTTT 0 ^20 720 v <sup>2</sup>	570 v58 IGCAGAGCCTAT IIIIIIIIII IGCAGAGCCTAT ^30 720 v74 IGGAGCCGGGCC	0 v590 CACCCCTC660 1111111111 CACCCCTC660 ^40 0 v750 AGCCGAGCGA	0 v600 CTCTGTAAAG IIIIIIIIIII CTCTGTAAAG ^50 0 v760 CTAAGCAAGG	0 v610 IATTICAGAIC IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	v620 CGGATAATTCA CGGATAATTCA CGGATAATTCA 70 v780 CGAAGAGTGTC	v630 ACCCTTACTGC ^80 √750 AAAGCCCCCCC	v€40 CCAGGCAAGGGG ^90 v800 TTCATGTACA0	v650 CACCCAAGTT CACCCAAGTT ^100 v810	v660 CCCAGAGTT CCCAGAGTT CCCAGAGTT ^110 v820	v670 CCTGCTGCCG CCTGCTGCCG ^120 v820	v680 SCCTGCATTT SCCTGCATTT ^130 v840 SCCGCTTGAA	v690 ATTAAAGTCG IIIIIIIIII ATTAAAGTCG ^140 v850 ATCCCATCCC		) CGCTC 11111 CGCTC ^160
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1	v550 v GGAGAGGGGGAA I I II GAAAGACGGGGCT ^1( v710 v GCTGGTAGCCTT	7560 vi NANAGTGCTTT TATAGTGCTTT 0 ^20 v720 vi TCACCCCGAAG	570 v58 IGCAGAGCCTAT IGCAGAGCCTAT ^20 730 v74 5TGAGCCGGGCC	0 v59 caccctc666 ^40 0 v75 acccaccac	0 v600 CTCTGTAAAG CTCTGTAAAG ^50 0 v760 CTAAGCAAGG	0 v610 IATTICAGAIC IATTICAGAIC ^60 0 v770 SAGGGGCGGGGG	v620 CGGATAATTCA CGGATAATTCA ^70 v780 CGAAGAGTGTC	v630 ACCCTTACTGC ^80 √790 AAAGGCCCCCC	+€40 CCAGGCAAGGGG ^90 +800 TTCATGTACAG	v650 CACCCAAGTT CACCCAAGTT ^100 v810 CAAACACACC	v660 CCCAGAGTT CCCAGAGTT ^110 v820 CCCTCCCAG	v670 cctGctGccd cctGctGccd ^120 v830 cccctcccAd	v680 GCCTGCATTT. GCCTGCATTT. ^130 v840 GCGCTTTGAA	v690 ATTAAAGTCG IIIIIAAAGTCG ^140 v850 ATCCCATCCC	v700 ICTGCTATAA ICTGCTATAA ^150 v860 GGCTITGTTG	CGCTC LIIII CGCTC ^160 TCTCC
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F	v550 GGAGAGGGGCAN I I II GAAAGACGGGCT ^11 v710 GCTGGTAGCCTI IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	7560 vi NANAGIGCTITI TATAGIGCTITI 0 ^20 v720 vi TCACCCCGAAG	570 v58 TGCAGAGCCTAT IGCAGAGCCTAT 100 100 100 100 100 100 100 10	0 v59 caccccrc666 ^40 0 v75 accc6a6c6a6 accc6a6c6a6	0 v600 CTCTGTAAAG CTCTGTAAAG ^50 0 v760 CTAAGCAAGG CTAAGCAAGG CTAAGCAAGG	0 v610 IATTTCAGAIC IATTTCAGAIC ^60 0 v770 SAGGGCGGGGG IAGGGCCGGGGG	v620 CGGATAATTCA CGGATAATTCA ^70 v780 CGAAGAGTGTC	v620 ACCCTTACTGC ^80 v790 AAAGGCCCCCC	+€40 ************************************	v650 CACCCAAGTT CACCCAAGTT ^100 v810 CAAACACACCAC	v660 cccAGAGTT () () () () () () () () () () () () ()	v670 cctGctGcci cctGctGcci ^120 v830 cccctCccA	v680 SCCTGCATTT GCCTGCATTT ^120 v840 SCGCTTTGAA	v690 ATTAAAGTCG 11111111 ATTAAAGTCG ^140 v850 ATCCCATCCC	v700 TCTGCTATAN TCTGCTATAN ^150 v860 GGCTTTGTTG	) (CSCTC ) ) (CSCTC ^160 ) TCTCC ) ) TCTCC
В	Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F	9550 GGAAGGGGAJ GAAAGACGGGCT 11 9 9 9 9 9 9 9 9 9 9 9 9 9	2560 vi AAAAGTGCTTT 1 11111111 CATAGTGCTTTT 0 ^20 v720 vi CACCCCGAAG4 111111111111111111111111111111111111	570 v58 TGCAGAGCCTAT 11111111111111111111111111111111111	0 v590 caccctrcsso 111111111 cacccctrcsso ^40 0 v750 ascccaacsao 111111111 ascccaacsao ^200	0 v600 CTCTGTAAAG CTCTGTAAAG ^50 0 v760 CTAAGCAAGG CTAAGCAAGG ^210	0 v610 TATTICAGAIC 111111000 101111000 10111000 10111000 1010000 1010000 101000 100000 100000 100000 100000 100000 100000 100000 100000 1000000 1000000 1000000 1000000 10000000 100000000	v620 CGGATAATTCA CGGATAATTCA CGGATAATTCA ^70 v780 CGAAGAGTGTCC CGAAGAGTGTCC ^220	v€30 ACCCTTACTGC ^80 v790 UAAGGCCCCCC ^240	v640 CCAGGCAAGGGG ^90 v800 TTCATGTACAG 	v650 CACCCAAGTT ^100 v810 CAAACAACACC CAAACAACACACC ^260	v660 CCCAGAGTT 110 v820 CCCTCCCAG CCCTCCCAG 2270	v670 cctsctscct 110 120 v830 cccctcccA 280	vé80 SCCTSCATTT. ^130 v840 SCGCTTTGAA 	v690 ATTAAAGTCG 11111111 ATTAAAGTCG 140 v850 ATCCCATCCC 111111111 ATCCCATCCC 200	v700 ICTGCTATAA ^150 v860 SGCTTIGTTO ^210	) LCSCTC 11111 LCSCTC 1160 ) TCTCC 11111 TCTCC 2220
В	Muman DEK1 062074-BA-024-1-131-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F	v550 cs. cs.ks.scs.cs.cs. i i i i cs.ks.cs.cs.cs. °10 v710 cs. cc.cs.cs.cs.cs.cs. i i i i i i i i i i i i i i i i i i i	2560 vi AAAGTGCTTTT ATAGTGCTTTT 0 ^20 720 vi TCACCCCGAAG4 70 ^180 2800 vi	570 v58 recAGAGCCTAT	0 v59 caccectess 1111111 caccectess ^40 0 v75 Ascesasess 1111111 Ascesasess 200 0 v91	0 v600 CTCTGTAAAG7 CTCTGTAAAG7 50 0 v760 CTAAGCAAG60 CTAAGCAAG60 210 0 v920	0 v610 FATTICAGATC IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	v620 CGGATAATTCA CGGATAATTCA CGGATAATTCA ^70 v780 CGAAGAGTGTCC CGAAGAGTGTCC 230 v940	v630 ACCCTTACTGC 100 100 100 100 100 100 100 10	v640 CCAGGCAAGGGG ^90 v800 TTCATGTACAG ^250 v960	v650 CACCCAAGTT ^100 v810 CAAACACACCC CAAACACACCC ^260 v970	v660 cccAgAgTT ^110 ^110 v820 ccctcccAg 1111111 ccctcccAg 270 v980	+670 ccr6cr6ccr ^120 +820 ccccrcccA 1111111 ccccrccA ^280 -990	v680 SCCTSCATTT. 1100 SCCTSCATTT. 120 v840 SCSCTTTSAA SCSCTTTSAA 2290 v100	v690 ATTAAAGTCG 11111111 ATTAAAGTCG 140 v650 ATCCCATCCC 11111111 ATCCCATCCC 300 v101	v700 rctgctataa ntso v860 scctttgttg scctttgttg scctttgttg 200 v100	) CGGCTC 11111 CGGCTC 160 TCTCC 11111 TCTCC 320
В	Human DKK1 062074-BA-024-1-131-DKK1-F Human DKK1 062074-BA-024-1-131-DKK1-F Human DKK1	v550 GGAAGGGGCAJ I I II GAAAGACGGGCT ^10 GCTGGTAGCCTT UIIIIIIIII GCTGGTAGCCTT v070 v770 v770 cTCCCAAGGGGG	2560 vi LAXAGGCTIT: 1 1111111 1 1111111 1 11111111 1 11111111	570 v58 IGCAGAGCCTAT 1000 1	0 v59 caccetress ^40 0 v75 Ascecasesa ^200 0 v91 Tabasecas	0 v600 CTCTGTAAAG CTCTGTAAAG ^50 0 v760 CTAAGCAAGGO ^210 0 v920 CCCCGTGTGGOC	0 v610 TATTTCAGATC 1111111111 TATTTCAGATC ^60 0 v770 5ASGSGCGGGGG ^220 0 v920 0 v920	v620 CGGATAATTCA CGGATAATTCA 70 v780 CGAAGAGTGCC CGAAGAGTGCC 230 v940 MGAGCTCTGTG	v630 ACCCTTACTGC *80 v790 AAAG6CCCCCC *240 v950 TCCCT6CA6T	v640 CCAGCCAAGGGG ^90 v800 v700 v700 v700 v700 v700 v960 v960 v960 v960 v960	v650 CACCCAAGTT ^100 v810 CAAACACACC ^260 v970 SGACCCAGG	v660 cccAGAGTT ^110 v820 cccccccAG 1111111 cccccccAG ^270 v980 ssectoccs	+670 CCTGCTGCCG ^120 +830 CCCCTCCCA ^280 +990 GACCTGAC	v680 SCCTGCATTT. ^120 v840 SCGCTTTGAA SCGCTTTGAA ^290 v100 TCTGCAGCCS	v690 ATTAAAGTCG 111111111 ATTAAAGTCG 140 v850 ATCCCATCCC 200 0 v101 ACCCCACCCC 0 v101	v700 rctgctataa rctgctataa *860 sgcttigtto '210 0 v102	) CGCTC 11111 CGCTC 160 TCTCC 11111 TCTCC 220 0 0 0 0 0
В	Muman DER1 062074-BA-024-1-131-DER1-E Muman DER1 062074-BA-024-1-131-DER1-E	v550 GAAAGAGGGCAA GAAAGACGGGCT 1 GAAAGACGGGCT 1 0 0 0 0 0 0 0 0 0 0 0 0 0	7560 vi AAAAGTGCTTT: 0 ^20 vi CACCCCGAAGG 111111111111111111111111111111111	570     v58       rgcAgAgeCtAt	0 v59 CACCCTCG64 ^40 0 v75 AGCCGAGGGA ^200 0 v91 ATAAAGCAG	0 v600 CTCTGTAAAG1 ^50 0 v760 CTAAGCAAG66 () CTAAGCAAG66 ^210 0 v920 CCGCGGTGGCC	0 vél0 TATTICAGATC ^60 0 v770 SASGSGCGSGG 111111111 SASGSGCGSGGG 220 0 v930 SGTGGCGGGGGC	v620 CGGATAATTCA CGGATAATTCA ^70 v780 IGAAGAGTGTC 111 111 111 111 111 111 111 1	v630 ACCCTTACTGC ^80 v790 NAAGGCCCCCC 240 v950 TCCCTGCAG	v640 CCAGGCAAGGG4 ^90 v800 TTCATGTACM '11 TTCATGTACM '250 v960 CCAGGACTCTG	v650 CACCCAAGTT ^100 v810 CAAACACACC ^260 v970 SGACCGCASG	v660 CCCAGAGTT (110 v820 CCCTCCCAG 270 v980 SGGCTCCCG	v670 ccr6cr6cc ^120 v830 ccccr6ccA ^280 v990 5Acccr6Ac	vé80 SCCTGCATTI ^130 v840 SCGCTITGAA GCGCTITGAA ^290 v100 TCTGCASCCG	v690 ATTAAAGTCG ^140 v850 ATCCCATCCC ^300 0 v101 AACCGGCACG	v700 ICTGCTATAA ^150 v860 SGCTIIGTTO ^210 0 v102 STITCGTGGG	) CGGCTC 11111 CGGCTC 160 TCTCC 11111 TCTCC 1220 10 10 11111
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F	v550 GSAGAGGGGCA I I I GAAAGACGGGCT GCTGGTAGCCTT CTCCCAAGGGGG CTCCCAAGGGGG	7560 vt AAAGTGCTTTT CATAGTGCTTTT 0 200 720 vt rCACCCCGAAG 100 100 100 100 100 100 100 10	570 v58 GCGGAGACCTAT GCCAGAGCCTAT TGCAGAGCCTAT 100 v74 5TGAGCCGGGCCC 0 v74 5TGAGCCGGGCC 0 v50 50 v50	0 v59 CACCCTCG64 ^40 0 v75i AGCCGAGCGA4 AGCCGAGCGA4 0 v91i ATAAAGCCA64 ATAAAGCCA64	0 v600 CTCTGTAAAS1 ^S0 0 v760 CTAAGCAAGG4 CTAAGCAAGG4 2210 0 v920 CCGCGGTGGC0	0 v610 TATTICAGATC *60 0 v770 5ASGGCCGGGG 1100 5ASGGCCGGGG 0 v920 5GTGGCGGCGCGC	v620 CGGATAATTCA ^70 v780 CGAAGAGTGTC: ^230 v940 AGAGCTCTGTG	v630 ACCCTTACTGC ^80 v790 NAASGCCCCCCC ^240 v950 TCCCTGCAGT	v640 CCAGGCAAGGG4 ^90 v800 TTCATGTACA4 ^250 v960 CCAGGACTCTG4	v650 CACCCAAGTT ^100 v610 CAACACACC ^260 v970 SGACCGCAGG	v660 CCCAGAGTT 110 110 v820 CCCTCCCAG 270 v980 SGGCTCCCG SGGCTCCCG	v670 ccrGcrGccrGccr ^120 v830 ccccrcccA 280 v990 GACCCTGAC	v680 SCCTSCATTT. ^130 v840 SCCCTTTGAA v840 SCCCTTTGAA ^290 v100 ICTGCASCCG	v690 ATTAAAGTCG ^140 v850 ATCCCATCCC iiiiiii ATCCCATCCC 0 v101 AACCGGCACG	v700 TCTGCTATAA ^150 v860 GCTTIGTTC GCTTIGTTC 300 v102 STTTCGTGGG	CGCTC 
В	Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F	v550	7560 vt AAAGTGCTTT: ATAGTGCTTT: 0 200 100 1000 1	570 +58 FCCASAGCCTAT 100 100 100 100 100 100 100 10	0 v59 caccectege caccectege 40 0 v75 Ageogage 200 0 v91 Attaageoga Attaageoga 200 0 v91 Attaageoga 200 0 v91 Attaatageoga 200 0 v91 0	0 v600 CTCTGTAAAG7 ^50 0 v760 CTAAGCAAG60 ^210 0 v920 0 v920 CC0CC6GT6GCC CC0CC6GT6GCC 270	0 v610 PATTICAGATC ^60 0 v770 5ASGSGCSGSGS ^220 0 v920 5GTGSCGSGCG SGTGSCGSGCGC 0 v220 0 z20 0 z	v620 CGGATAATTCA ^70 v780 CGAAGAGTGTC ^230 v940 AGAGCTCTGTG ^290	v630 ACCCTTACTGC ^80 v790 HAAGGCCCCCC ^240 v950 TCCCTGCAGT -240	v640 v640 ccAssCAAsss ^90 v800 tTCATGTACA ^250 v960 v960 cCAssActCTS ccAssActCTS ^410 ccAssActCTS ~410 ~410 ~410 ~410 ~410 ~410 ~410 ~410	v650 CACCCAAGTT '100 v810 CAAACACACC '260 v970 SGACCGCAGG GGACCGCAGG '420	v660 CCCAGAGTT ^110 v820 CCCTCCCAG ^270 v980 SGGCTCCCG ^220	v670 ccrscrscci ^120 v820 ccccrcccAi ^280 v990 sAcccrGAC ^440	v680 scctscattt. ^130 v840 scsctttgaa 290 v100 tctscAsccs ^450	v690 ATTAAAGTCG ^140 v650 ATCCCATCCC ^200 0 v101 AACC6GCACG ^240	v700 ICTGCTATAA ^150 v860 SGCTITGTTC ^210 v102 STITCGTGGG 0 v102 STITCGTGGG 0 2470	CGGCTC 1100 CGGCTC 160 TCTCC 100 TCTCC 100 TCTCC 100 TCTCC 100 TCTCC 100 TCTCC 100 TCTCC 100 100 100 100 100 100 100 1
В	Human DERI 062074-BA-024-1-131-DERI-F Human DERI 062074-BA-024-1-131-DERI-F Human DERI 062074-BA-024-1-131-DERI-F	v550 GAAAGGGGCAJ 	7560 vi MAAAGTGCTITI CATAGGCTITI CATAGGCTITI CATAGGCTITI CACCCCGAAG COCCCGAAG COCCCGAAG COCCGGAATGCTCC COCGGAATGCTCC COCGGGAATGCTCCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGGAATGCTCC COCGGAATGCTCC COCGGAATGCTCC COCGGAATGCTCC COCGGAATGCTCC COCGGAATGCTCC COCGGAATGCTCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCC COCGGAATGCCCCCCCC COCGGAATGCCCCCCC COCGCACTCCCCCCCCCCCC COCGCACTCCCCCCCCCCCCCCCC COCGCCCCCCCCCCCCCCCCCC	570 v58 TGCASAGCTAT 100 100 100 100 100 100 100 10	0 v59 cAcccctrcssc ^40 0 v75 AsccsAccSA AsccsAccSA 0 v91 AttAAAScCAS ^200 0 v91 AttAAAScCAS ^200 0 v91 AttAAAScCAS ^200 0 v91 0 transformed 0 transfor	0 v600 CTCTGTAAAG ^0 v760 CTAAGCAAGG 0 v920 CTAAGCAAGG 0 v920 CCCCGGGGGGGGC ^210 0 v920 CCCCGGGGGGGGC ^270 v100	0 v610 IATTICAGATC IATTICAGATC °0 0 v770 0 x770 0 x770	v620 CGGATAATTCA ^70 TGAAGAGTGTCI ^20 v940 NGAGGTCTGTG ^390 v1100	v630 ACCCTTACTGC *80 v790 HAASGCCCCCC *240 v950 TTCCCTGCAST *400 v1110	v640 CCAGGCAAGGG ^90 v800 TTCATGTACA ^250 v960 CCAGGACTCTG ^410 v1120	v650 CACCCAAGTT '100 v810 CAAACACCACC '260 v970 GGACCGCAGG '420 v1120	v660 cccAgAgTr ^110 v820 cccrcccAg 11111111 cccCAgAgTr ^820 cccrcccAg v820 v980 ssscrccccag v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccag *270 v980 ssscrccccccag *270 v980 ssscrcccccag *270 v980 ssscrcccccccccag *270 v980 ssscrccccccccccccccag *270 v980 ssscrccccccccccccccccccccccccccccccccc	v670 cctGctGcct ^120 v820 cccctcccA ^280 v990 SACCCTGAC ^440 v115	v680 GCCTGCATTT. ^130 v840 GCGCTTTGAA 1000 GCGCTTTGAA ^290 v100 TCTGCAGCCG ^450 0 v116	v690 ATTAAAGTCG ^140 v850 ATCCCATCCC 111111111 ATCCCATCCC ^200 0 v101 AACCGGCACG ^460 0 v112	v700 rctGCTATAM ^150 v860 5GCTTIGTIO ^210 0 v102 5TTTCGTGGG 0 v102 5TTTCGTGGG 0 v102	) CCGCTC 111111 CCGCTC 1400 TCTCCC 111111 TCTCC 10 CCGCTC 140
В	Muman DEK1 062074-BA-024-1-131-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F	v550     v       GALASSEGCIA     11       i     11       GALASSEGCIA     121       v710     v       GCTEGTASCCTI     11       v870     121       v800     121       v100     121       v1000     121	2560 vi LAAAGTGCTITI 1 1111111 CATAGTGCTITI 0 200 7720 v <sup>2</sup> 1720 v <sup>2</sup>	570 +58 TGCAGAGCCTAT ^20 730 +74 5TGAGCCGGCCT 5TGAGCCGGCC 0 190 950 +50 5GGGCCCGCGGCT 1000 +50 500 +50 500 +50 500 +50 1000 +50 500 +500 +500 500 +50	0 v59 caccectess caccectess 40 0 v75 Asecesacesa ^200 0 v91 Athansecas 11 Athansecas 360 60 v10	0 v600 CTCTGTANAG CTCTGTANAG 0 v760 CTANGCANGG ^210 0 v920 CCGCGGTGGCC 100 200 200 200 200 200 200 200	0 v610 rATTICAGATC rATTICAGATC 60 0 v770 5AS656C56666 220 v930 55T56C566C6 1111111111 55T56C56C6CC 280 20 v109 20 v1	v620 COGATAATTCA ^70 v780 CGAAGAGTGTC ^220 v940 AGAGCTCTGTG ^230 v940 0 v1000 v1000 v1000	v630 ACCCTTACTGC *80 v790 HAASGCCCCCC *240 v950 TCCCTGCAST *400 v1110 v1100	v640 CCAGCAAGGG '90 v800 TTCATGTACAA '250 v960 CCAGGACTCTG CCAGGACTCTG '4100 v1120	v650 CACCCAAGTT ^100 v510 CAACCAAGTC ^200 v970 SGACCGCAGG ^420 v1120 cGACCGCAGG ^420 v1120	v660 cccsAsAstr '110 v200 ccctAsAstr '110 v200 ccctcccAs '270 v980 sesctcccs '420 v1140	v670 ccrecrecci ^120 ^120 v630 cccrcccca ^280 v990 SACCCrGAC ^440 v115	v680 GCCTGCATTT. ^120 v840 GCGCTITGAA ^290 v100 TCTGCASCCG ^450 0 v116	v650 ATTAAAGTCG ^140 v650 ATCCCATCCC ^200 v101 AACCGGCACG ^460 0 v117 AACCGGCACG ^460 0 v117		CGCTC (1111) (CGCTC (CGCTC (CGCTC (110) TCTCCC (110) TCTCCC (110) TCTCCC (110) TCTCCCCCC (110) TCTCCCCCC (110) TCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
В	Human DERI 062074-BA-024-1-131-DERI-F Human DERI 062074-BA-024-1-131-DERI-F Human DERI 062074-BA-024-1-131-DERI-F	v550 ***********************************	560 v: hAAGTGCTIT: CATAGGTIT	570 +58 TGCASAGCTAT ^30 720 +74 5TGASCCGGGCC 0 190 0	0 v59 CACCCTC666 ^40 0 v75 AGCCGAGCGA AGCCGAGCGA 0 v91 ATAAAGCAG 0 v91 ATAAAGCAG 0 v10 TCTCCCTTT	0 v600 CTCTGTAAAG ^S0 0 v760 CTAAGCAAGGO 0 v920 CCGCGGGGGGGGC 210 0 v920 CCGCCGGGGGGGGC 270 0 v100 GAGTCCTTCT	0 v610 TATTICAGATC ************************************	v620 CGGATAATTCA ~70 ~780 rGAAGAGTGTC ~2940 GGAGCTCTGTGG ~390 0 v1100 rCTGGGCCCAG	v630 ACCCTTACTGC ^80 v750 v40 v950 rtccctGcAst ^400 v1110 rccGGAscTAcC	v640 CCAGGCAAGGG ^90 v800 CTTCATGTACM ^250 v960 CCAGGACTCTGG ^410 v1120 CCAGGACTCTGG	v650 CACCCAAGTT ^100 v810 CAAACACACCC ^260 v970 SGACCGCAGGG ^420 v1120 CGCGATGGT.	v660 cccA6A6TT ^110 v820 cccTccCA6A6TT ^120 v920 cccTccCA6 °270 v990 secTcCC6 secTcCC6 secTcCC6 v120 v1140 x6C6C6C6C	v670 ccrtecrecci ^120 ve320 ccccrtecck ^280 v990 5ACCCT6AC ^440 v115 rcrcesces	v680 SCCTGCATTT. ^130 v840 SCGCTTTGAA ^290 v100 TCTGCASCCG ^450 0 v116 CCACCCTCTG	v650 ATTAAAGTCG ^140 v850 ATCCCATCCC 0 v101 AACCCGCATCC 0 v101 AACCGGCACG ^460 0 v117 CTGGGAGTCA	v700 rcr6ctATAA ^150 v860 GGCTTIGTIG 310 0 v102 STITCGTGGG 470 0 v118 SGCCACCTI	) LCSCTC 11111 LCSCTC 160 STCTCC 100 SGACCC 101 SGACCC 100 100 SGACT
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1	v550	2560 v: LAAAGTGCTTT: CATAGTGCTTT: 0 200 7200 v: 7200	570 v58 TGCAGAGCCTAT ^20 730 v74 TGAGCGGGCC 110 57GAGCCGGGCC 0 190 950 v50 0 190 0 v50 0 250 1050 v100 0 250 1050 v100 0 250 1050 v100 1050 v100 10	0 v59 caccottoss 11111111 caccottoss ^40 0 v751 Ascotsaccsa ^200 0 v911 AttaAssccas 111111111 AttaAssccas 0 v10 0 v10 11111111111111111111111111111111111	0 v600 CTCTGTAAAG ^50 0 v76( CTAAGCAAGGG ^210 0 v92( CCCCGGTGGCC ^270 70 v100 0 v502 CCCCGGTGGCC ^270 70 v100	0 v610 TATTICAGATC 'CO 0 v770 5ASGEGCEGEGE 220 0 v520 5GTGECEGEGEC 230 80 v109 5GASTATATOSC 1100000000000000000000000000000000000	v620 CCGATAATTCA ^70 v780 cCAACAGTGTC 220 v540 cAGCTCTGTG 390 v1000 v1000 cTCGGCCCGCAG	v630 v600TTACTSC ~80 v790 uAASSCCCCCCC ~240 v950 TCCCTSCAST ~400 v1110 ~600 v1110 ~600 v1110	v640 CCAGGCAAGGGG '90 v800 'TTCATGTACM '250 v960 CCAGGACTCTGG '410 v1120 CCAGGACTCTGG '410 v1120 CCAGGACTCTGG '410	v650 CACCCAASTT ^100 v910 CAAACACACC ^260 v970 SGACCGCAGG ^420 v120 coCGATGGT 0 0 0 0 0 0 0 0 0 0 0 0 0	v660 CCCAGAGTT CCCAGAGTT ^110 v820 cCCTCCCAG ^270 v980 sescTCCCG ^420 v140 sescTCCCG	v670 ccreatesco ^120 v630 cccctccca 280 v950 5Accct6Act ^440 v115 cccscscs v440 v115 cccscscs v115	v680 scctscAttt '120 v540 scsctttsAA '250 v100 rctscAsccs '450 0 v116 cocctttsAA '450 0 v116 coccctttsAA	v690 ATTAAAGTCG 140 v8500 ATCCCATCCC 200 0 v101 ATCCCGCATCCC 460 0 v101 TGGGGATCG 1000 v117	v700 rcr5cr1ATAJ	) (CSCTC 1100 CCSCTC 1200 CTCTCC 2200 CSACCC 100 CSACCC 100 CSACCC 100 100 100 100 100 100 100
В	Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F	v550		570 +58 FCCAGAGCCTAT ^20 720 +74 5TGAGCCGGGCC 0 190 950 +90 550 +90 550 +90 550 +90 1050 +10 1050 +10 10	0 v59 cAccectrosse ^40 0 v75 Ascesacesak ^200 0 v91 AttAbasecas 0 v91 AttAbasecas 0 v10 Tereceretti Tereceretti Tereceretti	0 v600 CTCTGTAAAG ^50 0 v76( CTAAGCAAGGC ^210 0 v92( CCGCGGGGGGGCC ^270 70 v100 GAGTCCTTCTT GAGTCCTTCTT	0 v610 TATTTCAGATC *60 0 v770 5ASGSGCSGSGG 220 0 v920 5GTGSCSGCSCC 20 0 v920 5GTGSCSGCSCCCCCC 20 0 v920 5GTGSCSCSCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	v620 CGGATAATTCA ^70 v780 rGAAGAGTGTC ^220 v940 AGAGCTCTGTG ^290 v940 AGAGCCCTGTG	v630 ACCCTTACTGC ^80 v750 LAAGGCCCCCC ^240 v950 CTCCCTGCAGT ^400 v110 CGGGAGCTA- 2560	v640 CCAGGCAAGGG '90 v800 TTCATGTACA '250 v960 CCAGGACTCTGG '410 v1120 CCGGCTCTTGG '410 v1120	v650 CACCCAAGTT '100 v810 CACAAGTT '200 v970 V970 V970 V970 V970 V970 V970 V970 V120	v660 cccAsAsTr ^110 v820 cccTcccAs ^270 v80 ssscTcccs ·420 v1140 Ascesses	v670 CCTGCTGCC 120 v830 cccCTCCCA v990 5ACCCTGAC 440 v115 CCCGGGGGG v115 cccGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	v680 scctscAttt '130 v840 scsctttGAA v250 v100 rctscAsccs rctscAsccs 0 v116 ccAccetcts ccaccetcts ccaccetcts v200	v690 ATTAAAGTCG '140 v850 ATCCCATCCC '200 0 v101 AACC6GCACG 0 v101 CTCGGAGCGACG 0 v117 CTGGGAGCGACG CTCGGGAGCGACGACGACGACGACGACGACGACGACGACGAC	v700 CCTGCTATATA 150 v860 SGCTTIGTTO 210 0 v102 STITCGTGGG 470 0 v102 SGCCACCTT 470 0 v102 SGCCACCTT 200	) LCSCTC 160 FTCTCC 320 0 FTCTCC 10 10 10 FTCTCC 10 FTCCC 10 FTCCC 10 FTCCC 10 FTCCC 10
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F	v550 ***********************************		570 +58 FOR -500 F	0 v59 cAccetress ^40 0 v75 AscesAccsAc ^200 0 v910 ATAAASCAS 60 v100 TETECETETT *200	0 v600 CTCTGTANAGT ^S0 0 v760 CTAAGCAAGGO 0 v920 CCGCGGGGGGGGC ^370 0 v920 CCGCGGGGGGGGC ^370 0 v100 GAGTCCTTCTC -520 0 v100 0 cgGCGTTCTC -520 0 v100 0 cgGCGTTCTC -520 0 v100 0 cgGCGTTCTC -520 0 v100 0 cgGCGTTCTCTC -520 0 v100 0 cgGCGTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	0 v610 TATTICAGATC TATTICAGATC ************************************	v620 CGGATAATTCA TCO TGAAGAGTGTC 100 100 100 100 100 100 100 10	v630 ACCCTTACTGC ^80 v790 v40s v250 rtccctgcAst ^400 v1110 rtccctgcAst ^400 v1110 rtccctgcAst ^600 v1110 rtccctgcAst ~100 v1110 rtccctgcAst ~100 v1110 rtccctgcAst ~100 v1110 rtccctgcAst ~100 v110 rtccctgcAst ~100 rtccctgcAst ~100 ~100 rtccctgcAst ~100 ~100 ~100 ~100 ~100 ~100 ~100 ~100 ~100 ~100 ~100	v640 CCAGGCAAGGGC ^90 v800 CTTCATGTACAG 250 v960 CCAGGACTCTGG ^410 v1120 CCAGGACTCTGG ^1120 CCTTGGT CCAGGACTCTGG ~1120 CCTTGGT ~12500~1250 ~12500~1250 ~12	v650 CACCCAAGTT CACCCAAGTT '100 v810 '200 v910 '200 v970	v660 cccAsAstT cccAsAstT 110 v820 cccrcccAs 270 v980 ssscrcccss 420 v1100 ssscrcccss v1100 Accsscssc 0 0 0 0 0 0 0 0 0 0 0 0 0	v670 0crtecreece ^120 v820 cccccreece ^280 v950 sacccreace ^440 v115 rcrcescese rcrcescese ccccreace ************************************	v680 SCCTGCAITT '120 v840 v540 v100	v690 ATTAAAGTCG 140 v850 ATCCCATCCC 200 0 v101 AACC65CACG ^460 0 v117 CTG65AGT6A 40 0 v117 CTG65AGT6A 40 0 v117 CTG65AGT6A 40 0 v117 CTG65AGT6A 40 0 v117 CTG65AGT6A 40 0 v17 CTG65AGT6A 40 0 v17 CTG65AGT6A 0 v17 CTG65AGT6A 0 v17 CTG65AGT6A 0 v17 CTG65AGT6A C C C C C C C C C C C C C C C C C C C	v700 retGCTATAA '150 v860 sGCTTTGTG '210 0 v100 sTTTCGTGGG '470 0 v110 sTTTCGTGGG '470 0 v110 sTTTCGTGGG '470 0 v110 sTTTCGTGGG '470 '200	) (CSCTC 160 ) TCTCC 100 SGACCC 101 SGACCC 101 SGACT 101 SGAACT 101 101 101 101 101 101 101 10
В	Muman DEK1 062074-BA-024-1-121-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F Muman DEK1 062074-BA-024-1-131-DEK1-F	v550	2560 vi LAAAGTGCTITI CATAGTGCTITI 0 200 720 v <sup>2</sup> 0 720 v <sup>2</sup> 0	570 +58 TGCA6A6CCTAT ^20 720 +74 5TGA6CCG6CC 5TGA6CCG6CC 5TGA6CCG6CC 0 190 950 +50 5CG6CCCCCCCGC 100 +23 100	0 v59 cAccettesse ^40 0 v75 AccessAccsAc ^200 0 v91 AttAAsGeCAG ^260 0 v10 Tetecetett ^250 20 v10 Concetett	0 v600 CTCTGTAAAG ^S0 0 v76( CTAAGCAAGGC ^210 0 v92( CCGCGGGTGGCC ^370 70 v100 GAGTCCTTCTC ^320 20 v122 CGCGGGTGGCC ^320 0 v122 CGCGGGGTGGCC ^320 0 v124 CGCGGGGTGGCC ^320 0 v124 CGCGGGGTGGCC ^320 0 v104 CGCGGGGTGGCC ^320 0 v104 CGCGGGGGGGGGGGGC ^320 0 v104 CGCGGGGGGGGGGCC ^320 0 v104 CGCGGGGGGGGGGGGCC CGCGGGGGGGGGCC CGCGGGGGGGG	0 v610 TATTTCAGATC ^60 0 v7700 SASGSGCSGCSGC 0 v520 50TGSCCSGCCC 280 20 v109 55GSATGATGSCC 540 40 v125	v620 COGATAATTCA ^70 v780 CGAAGAGTGTC 220 v940 AGAGCTCTGTGG 230 v1100 rcTGGGCGCAG ^250 v1100 rcTGGGCGCAG ^550 v1220	v620 v600TTACTSC ^80 v790 v4790 v486500000 ^240 v950 TC00TSCAST ^400 v1110 c56565000 v12	v640 CCAGGCAAGGGG '90 v800 '250 v960 CCAGGACTCTG CCAGGACTCTG '410 v1120 CCAGGACTCTG '410 v1120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGACTCTG '410 v120 CCAGGCAAGGGG '410 '50 '410 '410 '50 '50 '50 '410 '50 '50 '50 '50 '50 '50 '50 '5	v650 CACCCAASTT 100 v810 XAACCAACC v710 v220 v770 x6ACCCAAG v770 x6ACCCAAG v1120 v1120 cccCaASTGST v1220 v1220	v660 CCCA6AGTT '110 v820 ccCTCCCA6 v980 sectrocca6 v110 v110 v110 seccrocca6 v1140 Accesecsc v1140 Accesecsc	v670 CCTGCTGCC 120 v830 cCCCTCCCA v280 v950 SACCTGAC v115 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGGG v121 rcTCGSCGG v121 rcTCGSCGG v121 rcTCGSCG v121 rcTCGSCG v121 rcTCGSCG v121 rcTCG v120 rcTCGC v120 rcTCGC v120 rcTCGC v120 rcTCGCCC v120 rcTCGCC v120 rcTCGCC v120 rcTCGCC rcTCGCC v120 rcTCGCCGCGG rcTCGCC v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCGG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG v120 rcTCGCCGCG rcTCGCCGCG rcTCGCCGCG rcTCGCCGCG rcTCGCCGCG rcTCGCGCG rcTCGCCGCG rcTCGCGCG rcTCGCGCGCG rcTCGCGCGCG rcTCGCGCGCGCGCG rcTCGCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC	v680 SCCTSCATTI '120 v840 SCCCTTGAN '250 v100 ICTSCASCCG '450 0 v116 CCACCCTCTG CCACCCTCTG CCACCCTCTG CCACCCTCTG '400 0 v123	v690 ATTANAGTCG 140 v850 ATCCCATCCC 200 0 v101 AACC65CACG 0 v101 CTG65AGTGA 0 v117 CTG65GAGTGA 0 v117 CTG65GAGTGA 0 v12 CTG65GAGTGA	+700 CCTCCTATATA ^150 +50 -150 -	CGGCTC 
В	Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F Muman DKK1 062074-BA-024-1-131-DKK1-F	v550 ***********************************		570 +58 FCCAGAGCCTAT	0 v59 cAccectross ^40 0 v75 AscesAccsAc ^200 0 v71 AtAAASCAG 0 v10 tercecterte 10 10 10 10 10 10 10 10 10 10	0 v600 CTCTGTAAAG ^50 0 v76( CTAAGCAAGGC ^210 0 v920 CCGCGGGGGGGGGG CCGCGGGGGGGGGGGG CCGCGGGGGGGG	0 v610 TATTTCAGATC ************************************	v620 CGGATAATTCA ~70 rGAAGAGTGTC ~280 v940 AGAGCTCTGTG ~290 0 v1100 CCTGGGGCGCAG ~550 0 v1260 GGCTCTGCAGT	v630 ACCCTTACTGC *80 v790 LAAGGCCCCCC *240 v950 TTCCCTGCAGT *400 v1110 CGGGAGCTA *560 v1270 CAGCGCCCCCCC	v640 CCAGGCAAGGG '90 v800 TTCATGTACA '250 v960 CCAGGACTCTGG '410 v1120 CCGGGCTCTTGG '5' '100 CCGGGAATCCTG '5' '120 CCGGGAATCCTG '5' '120 CCGGGAATCCTG	v650 CACCCAAGIT CACCCAAGIT '100 v810 CACCAAGIT '240 v970 v970 v970 v970 v970 v970 v1120 v1120 CACCAAGIT v1290 v1290 TLACCCAGG	v660 CCCA6ASTT CCCA6ASTT '110 v920 CCCTCCCAS '270 v980 ssscTTCCCS '420 v1140 Asccsccscc 0 ^ 1140 Asccsccscc 0 ^ v1200 SSSATTAS	v670 CCTGCTGCC CCTGCTGCC '120 v820 cccCTCCCA '280 v990 sACCCTGAC '440 v115 incrCGGGGGG 500 v121 incrCGGCGGG v120 v120 v120 v20 v20 v20 v20 v20 v20 v20 v	v680 scctscAttr. '130 v840 scsctttGAA '250 v100 cctscAsccs '450 v110 ccAccctcts '450 v110 ccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAccctcts '20 v111 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 v112 cccAcctts '20 cccc	v690 ATTAAAGTCG '140 v850 ATCCCATCCC '200 0 v101 AACCGCCATCCC '400 0 v117 CTGGGAGGAGGA '400 0 v117 CTGGGGAGGAGGA '410 0 v1 CTGGGGAGGAGGA '410 0 v1 CTGGGGAGGAGGA		) (CGCTC 1100 ) FCTCCC 100 100 FCTCCC 101 FCTCCCC 101 FCTCCCC 101 FCTCCCC 101 FCTCCCC 101 FCTCCCCC 101 FCTCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
В	Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F Human DEK1 062074-BA-024-1-131-DEK1-F	v550 GAAAGCGGCAA I I II GAAAGCGGGCA 11 v710 GCTGGTAGCCTI UUUUUUU GCTGGTAGCCTI CTCCCAAGGGGC CTCCCAAGGGGC  v070 CTCCCAAGGGGC  v070 cTCCCAAGGGGC  v070 v100 .	2560 v: LAAAGTGCTTTT: LATAGTGCTTTT: 0 200 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 7720 v' 720 v'	570 v58 FCCASAGCCTAT 100 120 120 120 120 150 150 150 150 150 150 150 15	0 v59 cAccettess 11111111 cAccetess 101111111111111111111111111111111111	0 v600 CTCTGTAAAG ^S0 0 v78( CTAAGCAAGGG ^210 0 v92( CCCCGGTGGCC ^210 0 v92( ^210 0 v92( ^210) 0 v92( ^210 0 v92( ^210) 0 v9	0 v610 TATTTCAGATC 111111111111111111111111111111111111	v620 CGGATAATTCA ^70 v780 cGAAGAGTGTC ^230 v940 cGAAGAGTGTCTGTG 390 v1000 v1000 cTGGGGCGCAG °50 v1200 v1200 v1200 v1000 cTGGGGCGCAG	v630 v600TTACTSC ~80 v790 uAASSCCCCCCC ~240 v950 TCCCTSCAST ~400 v1110 ~56GASCTACC ~560 v1270 ~560 v1270 ~500 ~500	v640 CCAGGCAAGGGG '90 v800 '1TCCATGTACAA '250 v960 CCAGGACTCTGG '410 v1120 CCAGGACTCTGG '410 v1120 '5' '5' '5' '5' '5' '5' '5' '5	v650 CACCCAASTT 100 v100 v100 v910 CAACCCAAGT -260 v970 SAACCCAAG v970 sAACCCACAG v970 v1120 cCCCGATGGT -420 v11290 x1290 x1290 -2200 -2000 -2	v660 CCCAGAGTT ^110 v820 ccCCCCCCAGAGTT ^110 v820 ccCCCCCCCAG v980 sGGCTCCCGA v980 sGGCTCCCGA v110 v1140 AGCGGCGGCC 00 v1140 AGCGGGCGCC 00 v1100 sGGATTAG	v670 CCTGCTGCCC '120 v830 CCCCTCCCA v980 v980 SACCCTGAC '280 v115 ICCCGGCCGAC '440 v115 ICCCGGCCGAC v410 v121 v120	v680 sccrscArr: 'lio v840 sccrrrGAA '290 v100 crcscAcccr '450 0 v116 ccAcccrcs '450 0 v116 ccAcccrcs '450 '450 '450 '450 '450 '450 '450 '450	v690 ATTANAGTCG 11111111 ATTANAGTCG 1210 v100 v100 NTCCCATCCC 1101111 NTCCCATCCC 11011111 NACCSGCACG v100 v	+700 CCTGCTATAM ^150 -250 -250 -250 -210	CGGCTC 
В	Human DEK1 062074-BA-024-1-131-DEK1-P Human DEK1 062074-BA-024-1-131-DEK1-P Human DEK1 062074-BA-024-1-131-DEK1-P Human DEK1 062074-BA-024-1-131-DEK1-P	v550		570 +58 FGCAGAGCCTAT ^20 720 +74 57GAGCCGGCCT 57GAGCCGGCCCC 0 190 550 +50 550 +50 550 +50 1050 +10 1050 +10 1050 +10 1050 +12 100 +12 CAGAGACCTACC 2000	0 v59 CACCCTC666 ^40 0 v75 AGCC6AGC6A ^200 0 v91 ATAAA6GCA6 ^200 60 v91 ATAAA6GCA6 60 v10 TCTCCCTCTT TCTCCCTCTT CCCACCCCTC 20 v12 CCCACCGCT6	0 v600 CTCTGTAAAG ^50 0 v760 CTAASCAASGS ^210 0 v920 CCGCGSGTGGCC ^210 0 v920 CCGCGSGTGGCC ^270 70 v100 GAGTCCTTCTC GAGTCCTTCTC GAGTCCTTCTC GAGTCCTTCTC GAGTCCTTCTC 0 v120 GCGCGGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 GCGCGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCTGG 0 v120 CCGCGGCGCCTGG 0 v120 CCGCGGCGCCTGG 0 v120 CCGCGGCGCCTCG 0 v120 CCGCGGCGCGCGCGCGCCC 0 v120 CCGCGGCGCGCGCGCG 0 v120 CCGCGGCGCCCGCGCGCGCCCCCCCCCCCCCCCCCCC	0 v610 TATTTCAGATC ^60 0 v770 5AG656C66666 220 0 v920 5GT66C66C6CC 280 80 v109 5AGATGAT66C 5AGATGAT66C 540 40 v125 5G66CACCCA	v620 CGGATAATTCA ^70 v780 CGAAGAGTGTC ^220 v940 AGAGCTCTGTG ^290 v1100 CCTGGGGCCAG ^250 v1100 CCTGGGGCCAG 0 v1260 SGCTCTGCAGT	v630 ACCCTTACTGC ^80 v750 LAAGGCCCCCC ^240 v950 TCCCTGCAGT ^400 v1110 CGGGAGCTA ^560 v1270 CGGGGGCCCGCCCCCCC v1270 CGGGGGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	v640 CCAGGCAAGGGG '90 v800 TTCATGTACAA '250 v960 CCAGGACTCTGG '410 v1120 CCGGGACTCTGG '2120 CCGGGATCCTG '57 v1280 CCGGGAATCCTG	v650 CACCCAAGTT '100 v810 CAACAACACC v670 v610	v660 v660 v100 v820 cccrcccAs v920 cccrccccAs v920 v920 sssscrcccs v920 v110 v120 v1200 sssstrccssc v120 v1200 sssstrccssc v210 v21	v670 CCTGCTGCC '120 v820 cccCTCCCA v920 v950 SACCCTGAC '440 v115 rCTCGGGGG v121 v120 v121 rCTCGGGGG v121 rCTCGGGGGG v121 rCTCGGGGGG v120 v120 v120 v120 v250	v680 SCCTGCATTT '130 v840 SCSCTTGAA '250 v100 TCTGCASCCG '450 0 v112 CCACCCTCTGG '600 0 v122 ATTGACAAA- TTGACAAACAAACAAACAAACAAACAAACAAACAAACAAA	v690 ATTAAAGTCG ^140 v850 ATCCCATCCC ^200 0 v101 AACCG6CACG 0 v101 CTGGGAGGGGG ^460 0 v117 CTGGGAGGGG ~610 0 v1 CTGGGGAGGGG ~610 0 v1 CTACCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG		CGGCTC 1111 CGGCTC 120 TCTCCC 101 103 104 105 105 105 105 105 105 105 105

Figure 3. Confirmation of *DKK1* exon-1 knock-out in Hep3B cells. A. Sanger sequencing results of gene knock-out in Hep3B CRISPR#73. B. Sanger sequencing results of gene knock-out in Hep3B CRISPR#131.



**Figure 4.** DKK1 increases the angiogenic effects of HUVECs. A. Effects of DKK1 exposure on tube formation in HUVECs. HUVECs were cultured in serum free media (negative control), growth media (positive control) and concentrated CM of Huh7 Pur-Mock, Huh7 Pur-DKK1, Hep3B wild-type and Hep3B CRISPR#73 cells (scale bar: 500 µm). Concentrated CM was harvested from Huh7 Pur-Mock and Pur-DKK1 cells 24 h after doxycycline treatment (100 ng/mL). B. Effects of DKK1 exposure on migration. HUVECs were cultured in concentrated CM from Huh7 Pur-Mock, Huh7 Pur-DKK1, Hep3B wild-type and Hep3B CRISPR#73 cells. Concentrated CM from Huh7 Pur-Mock, Huh7 Pur-DKK1, Hep3B wild-type and Hep3B CRISPR#73 cells. Concentrated CM from Huh7 Pur-Mock, Huh7 Pur-DKK1, Hep3B wild type and Hep3B CRISPR#73 cells. Concentrated CM from Huh7 Pur-DKK1 and Huh7 Pur-Mock cells was harvested 24 h after doxycycline treatment (100 ng/mL), Hep3B wild type and Hep3B CRISPR73 (a) and HUVECs were cultured in growth medium and concentrated CM from Hep3B wild type, CRISPR#73 and #131 cells (b). Bottom panel: Graphs show wound size. C. HUVECs lysates were probed with the indicated antibodies. HUVECs were stimulated with 100 ng/mL rDKK1 at each time point. GAPDH was used as loading control. D. HUVECs treated with 100 ng/mL rDKK1 were stained with anti-DKK1 (red) and DAPI (blue) (*P*<0.01). Ctrl: control (no treatment). E. HUVECs were treated with rDKK1 (100 ng/mL), quercetin (40 µM) and Quercetin (40 µM) + rDKK1 (100 ng/mL) (scale bar: 200 µM). Migration cells were quantified using ImageJ software. F. After starvation in serum-free medium for 6 h, HUVECs were pretreated with or without quercetin (40 µM) and 100 ng/mL rDKK1 for 1 h.



**Figure 5.** DKK1 enhanced the compactness and angiogenic effects of HCC-MCTS. A. Hep3B wild-type and CRISPR#73 cells were co-cultured with or without stromal cells (HUVECs: LX2: WI38) for 3 days (scale bar: 200 µm). To calculate the volume of the spheroids, the radius of spheroids of the Hep3B wild-type and CRISPR#73 cells co-cultured with stromal cells were measured (P<0.001) (right panel). B. H&E (scale bar: 50 µm) and IF staining (magnification, 200 ×) for DKK1 on the paraffin sections of HCC-MCTS. C. IHC and IF staining for CD31, vimentin, Slug, and E-cadherin on serial paraffin sections of HCC-MCTS (magnification, 200 ×). D. Lysates of MCTS generated using Hep3B wild-type and CRISPR#73 cells were probed with the indicated antibodies. GAPDH was used as a loading control.



**Figure 6.** DKK1 increased tumorigenesis in the xenograft mouse model. (A) Xenograft tumors generated using Hep3B CRISPR#73 cells exhibited slower growth, (B) smaller tumor volume and (C) smaller tumor weight (*P*<0.01) (n=10) than, the controls. (D) Kaplan-Meier survival curve of Hep3B wild-type and Hep3B CRISPR#73 tumor-bearing mice (each group, n=5). (E) DKK1 expression levels were detected using ELISA in the serum of the xenograft mouse models. (F) H&E (magnification, 200 ×) and IHC staining (magnification, 400 ×) for Ki-67 on serial paraffin sections of Hep3B wild-type and CRISPR#73 tumors. Graph of Ki-67 positive Hep3B stable cells (*P*<0.001).

### DKK1 promotes tumorigenesis in the xenograft mouse model

The xenograft mouse model was produced using Hep3B wild-type and CRISPR#73 cells to investigate whether DKK1 promotes tumorigenesis. Xenograft tumors generated using Hep3B CRISPR#73 cells (n=10) exhibited slower growth and smaller tumor volume and weight, than the controls (n=10) (Figure 6A-C). Subsequently, the xenograft mouse model using Hep3B CRISPR#73 showed better survival relative to the Hep3B wild-type (Figure 6D). Serum DKK1 levels were significantly higher in the model generated Hep3B wildtype cells than that generated using Hep3B CRISPR#73 cells (*P*<0.001) (**Figure 6E**). Immunohistochemistry (IHC) staining showed that Ki-67 expression levels in xenograft tumors generated using Hep3B wild-type cells were significantly higher than those in xenograft tumors generated using Hep3B CRISPR#73 cells (**Figure 6F**). These results indicate that DKK1 promotes HCC tumorigenesis by affecting tumor cell proliferation.

#### DKK1 promotes epithelial-mesenchymal transition makers in xenograft mouse model

To investigate the mechanism of HCC tumorigenesis by DKK1, we observed the angiogenesis and EMT markers of xenograft mouse

models using IF study. IF staining of serial sections of xenograft tumors showed that DKK1 expression levels in xenograft tumors generated using Hep3B wild-type cells were significantly higher than in those generated using Hep3B CRISPR#73 (P<0.05). In addition, the expression of angiogenesis markers, VEGFR2 and CD31, in xenograft tumors generated using Hep3B wild-type cells were significantly higher than in those generated using Hep3B CRIS-PR#73 cells (all P<0.05) (Figure 7A, 7B). The expression levels of mesenchymal markers of vimentin (P<0.05) and fibronectin (P<0.01) were significantly attenuated in xenograft tumors generated using Hep3B CRISPR#73 cells, compared to the controls, whereas the expression of the epithelial marker, E-cadherin, was significantly enhanced (P<0.05) in xenograft tumors generated using Hep3B CRIS-PR#73 cells, compared to the controls (Figure 7C, 7D). These results suggest that DKK1 increased the EMT markers in HCC.

### DKK1 enhanced tumor growth in the engineered mouse model

Hydrodynamic injection was performed to investigate the tumorigenic potential of DKK1. We previously confirmed that HCC is induced by the co-expression of HRAS<sup>G12V</sup> with a shRNA downregulating p53 in the liver [32]. To investigate the effects of DKK1 in the liver, we expressed DKK1 together with the aforementioned oncogenic combinations. The liver was harvested 5 weeks after hydrodynamic injection (Figure 8A), DKK1-2A-HRAS<sup>G12V</sup> + shp53 mice (HI\_DKK1 mice) (n=5) had significantly more tumors with larger size than those of luciferase-2A-HRAS<sup>G12V</sup> + shp53 mice (HI\_ Luc2A mice) (n=5) (Figure 8B). IHC staining showed that HRAS expression levels were similar between the HI\_DKK1 and HI\_Luc2A groups and that Ki-67 staining of HI\_DKK1 tumors was slightly higher than that of HI\_ Luc2A tumors (Figure 8C). The expression levels of downstream molecules of VEGFR2mediated mTOR/p70S6K signaling, were higher in HI\_DKK1 tumors than in HI\_Luc2A tumors (Figure 8D, 8E). In addition, IF staining showed that the expression levels of DKK1 and angiogenesis markers, VEGFR2 and CD31, were significantly increased in HI\_tumors compared to HI\_Luc2A tumors (all P<0.001) (Figure 9A, 9B). Moreover, expression levels of the epithelial marker, E-cadherin, was significantly attenuated and the mesenchymal markers of fibronectin were significantly enhanced in HI\_DKK1 tumors, compared to the control (all *P*<0.001) (**Figure 9C, 9D**). These results indicate that DKK1 promotes tumorigenesis and angiogenesis by upregulating VEGFR2-mediated mTOR/ p70S6K signaling and EMT markers in the mouse liver.

### Discussion

We previously reported that DKK1 promotes angiogenesis via VEGFR2 regulation [27]. However, the specific interaction between DKK1 and VEGFR2 in HCC remains to be ascertained. In this study, we first confirmed that rDKK1 increases the invasion of HUVECs and then established stable cell lines with regulated DKK1 expression. Second, we found that the tube formation and migration abilities of HUVECs were significantly enhanced upon treatment with concentrated CM with high DKK1 concentration. Third, a signaling study showed that DKK1 was correlated with the VEGFR2-mediated mTOR/p70S6K signaling pathway. Fourth, we also found that DKK1 enhanced spheroid compactness and EMT markers in HCC-MCTS models. In addition, we reported that DKK1 promoted angiogenesis and tumorigenesis in xenograft tumor and mouse liver, which was supported by the increased expression of endothelial and EMT markers, such as CD31, vimentin, fibronectin and decreased expression of E-cadherin. Based on these results, we concluded that DKK1 promotes angiogenesis and tumorigenesis via upregulation of VEGFR2-mediated mTOR/ p70S6K signaling and EMT markers.

Our study has several unique findings. First, our study provides additional support to the fact that DKK1 is significantly associated with angiogenesis of endothelial cells. To identify the angiogenic role of DKK1 in endothelial cells, we established stable cell lines using CRISPR/Cas9-based DKK1 knockout system in Hep3B and the tetracycline-based DKK1 inducible system in Huh7 cells. In Hep3B stable cell lines, two clones (Hep3B CRISPR#73 and #131) were selected because they were slightly smaller than the size of the upper part of the positive control band. Moreover, the Sanger sequencing results were used for selection. To date, the CRISPR-Cas9 system has shown great



**Figure 7.** DKK1 increased angiogenesis and EMT markers in the xenograft mouse model. A. Observation of IF staining for DKK1, VEGFR2 and CD31 on serial paraffin sections of xenograft tumors generated using Hep3B wild-type and CRISPR#73 with confocal microscopy. B. Quantification of DKK1 (P<0.05), VEGFR2 (P<0.05) and CD31 (P<0.05) IF, presented as the mean fluorescence intensity. C. Observation of IF staining for vimentin, fibronectin and E-cadherin on serial paraffin sections of xenograft tumors generated using Hep3B wild-type and CRISPR#73 cells with confocal microscopy. D. Quantification of vimentin (P<0.05), fibronectin (P<0.01) and E-cadherin (P<0.05) IF, presented as the mean fluorescence intensity.

potential for genome editing, but several limitations still exist [33]. For instance, homologydirected repair and insertion-deletion mutations in some genome sites have shown low efficiency. In addition, it has been found that some regions of the genome are not cut very well with CRISPR, and some cell types do not easily accept foreign DNA, RNA, or RNA-protein complexes [34]. All these factors might be associated with the minimal detection of DKK1 in our study. Nevertheless, the secreted DKK1 levels in Hep3B CRISPR#73 and #131 were significantly lower than those in Hep3B wild-type cells, which enabled us to investigate the effects of DKK1 inhibition on angiogenesis and tumorigenesis *in vitro* and *in vivo*. To date, it



**Figure 8.** DKK1 increased tumorigensis in the transgenic mouse model. A. DNA mixtures were injected into the lateral tail veins of 4-week-old mice and the livers were harvested at 9 weeks. B. Forced expression of DKK1 with HRAS in transgenic mouse liver resulted in the formation of more tumors (n=5), compared to the controls. C, D. H&E and IHC staining for HRAS, Ki-67, p-Akt and p-VEGFR2 on serial paraffin sections of HI\_Luc2A and HI\_DKK1 tumors (magnification, 200 ×). E. Lysates of HI\_Luc2A and HI\_DKK1 tumors were probed with the indicated antibodies. GAPDH was used as a loading control.



**Figure 9.** DKK1 increased angiogenesis and EMT markers in the transgenic mouse model. A. Observation of IF staining for DKK1, VEGFR2 and CD31 on serial paraffin sections of HI\_Luc2A and HI\_DKK1 tumors using confocal microscopy. B. Quantification of DKK1, VEGFR2 and CD31, presented as the mean fluorescence intensity. C. IF staining for vimentin, fibronectin and E-cadherin on serial paraffin sections of HI\_Luc2A and HI\_DKK1 tumors. D. Quantification of vimentin, fibronectin and E-cadherin, presented as the mean fluorescence intensity.

has been reported that DKK1 promotes the angiogenic effects of endothelial cells and fibroblasts [35, 36]. Smadja *et al.* [35] showed that DKK1 enhanced the proangiogenic potential of human endothelial colony-forming cells and these angiogenic effects have been attributed to enhancement of VEGFR2. In addition, Jiang *et al.* [37] showed that DKK1 is correlated with angiogenesis in fibroblasts through increased expression of VEGF and also found that HIF-1 $\alpha$  may be associated with DKK1 induced HUVECs migration. Our data similarly found that DKK1 raised the angiogenic potential of endothelial cells, which was supported by

the increased effects of HUVEC invasion, tube formation and migration. Our results showed that the angiogenic effects of HUVECs were increased by DKK1 in HCC cells.

Second, because we noticed a close association between DKK1 and angiogenesis, we focused on the mechanism involved. We found that DKK1 promoted HUVECs invasion and migration by upregulating VEGFR2-mediated mTOR/p70S6K pathway. mTOR expression is frequently upregulated in cancer, including HCC and is associated with poor prognosis, poorly differentiated tumors and early recurrence

[38]. In addition, Trinh et al. [39] determined that VEGF-A signaling acts on tumor cells as a stimulator of the Akt/mTOR pathway. Our results showed that DKK1 increased p-VEGFR2 and p-p70S6K protein levels in HUVECs. p70S6K, which is activated in signaling pathways that include mTOR, is significantly associated with HCC [40, 41]. Li et al. [40] suggested that the expression level of p-p70S6K was increased in HCC compared to that in cirrhotic nodules and normal liver tissue using immunostaining. In addition, Kristine et al. [42] showed that patients with breast tumors having increased expression of p-p70S6K showed increased metastasis and worse disease-free survival. In addition, to identify the effects of DKK1 in VEGFR2 signaling, we used the quercetin. In a previous study, Pratheeshkumar et al. [43] found that guercetin inhibited VEGFR2mediated Akt/mTOR/p70S6K signaling. We found that DKK1 combination of auercetin ameliorated VEGFR2-mediated Akt/mTOR/ p70S6K signaling and angiogenesis effects, compared to DKK1 alone. These results suggest that DKK1 promotes angiogenesis through VEGFR2-mediated Akt/mTOR/p70S6K signaling. Based on these results, our data suggest that the DKK1-induced VEGFR2 downstream pathway is involved in the angiogenesis of endothelial cells. Considering that DKK1 is a major player in VEGFR2-mediated mTOR/ p70S6K, DKK1 may be an attractive target for preventing the incidence of angiogenesis.

Third, we showed the influence of DKK1 on spheroid formation using Hep3B, HUVEC, LX2 and WI-38 cells. Our results reveal a striking correlation between the compactness ability of DKK1 and MCTS. In ovarian cancer cells, Katharine et al. [44] first indicated that a cell line possessing myofibroblast-like properties could form compact spheroids and subsequently, Katharine suggested that compact spheroid formation may facilitate ovarian cancer cell invasion. In addition, Cho et al. [45] found that YAP/TAZ levels were significantly different for each type of HCC-MCTS model, while Hep3B MCTS had the highest level of YAP/TAZ expression. YAP and TAZ are known to contribute to cell cycle [46] and Jorgenson et al. [47] reported that TAZ activation is associated with fibroblast spheroid growth. In summary, although Kelm et al. [48] reported an inverse association between tumor cell spheroid cohesiveness and invasive potential, a positive correlation between tumorigenicity and spheroid formation of cancer cells has been suggested [49]. Taken together, our MCTS results show that a DKK1-mediated increase in compactness, in addition to a rise in the expression levels of vimentin and Slug in MCTS, may promote cancer cell invasion. In addition, the relationship between YAP/TAZ and the ability of DKK1 including spheroid compactness should be further studied.

Fourth, we found that DKK1 leads to poor survival and there was an increase in the expression of angiogenesis and EMT markers in the mouse model, indicating the enhancement of angiogenesis and EMT markers upon DKK1 stimulation. Similar to the findings of the present study, Yao et al. [50] showed that in vasculogenic mimicry, DKK1 increases the expression level of EMT-related protein in non-small cell lung cancer. In addition, Maha et al. [51] found that since DKK1 facilitates tumor invasion and migration through transforming growth factor beta 1, it may induce EMT in HCC cell lines. Indeed, increasing evidence indicates a central role of EMT, which might occur at the leading edge of tumor cells, under particular factors derived from the tumor microenvironment in HCC [52]. In addition to EMT, DKK1 is significantly associated with endothelial-tomesenchymal transition (EndMT) [27, 53]. Previously, Choi et al. [27] found that DKK1 increases the expression of EndMT-related proteins (N-cadherin, Twist and vimentin) in endothelial cells and Cheng et al. [53] demonstrated that DKK1 enhances EndMT in aortic endothelial cells by augmenting ALK/Smad signaling to modulate the endothelial cell phenotype. In contrast, some studies have shown that EMT is negatively regulated by DKK1 [54-56]. In spite of this controversy regarding the interaction between DKK1 and EMT/EndMT [57, 58], based on the findings of our current study, we postulate that DKK1 may help to develop effective therapies against HCC.

There are several limitations to this study. First, our data show that DKK1 activates VEGFR2 downstream signaling, but only at the endothelial cell level. The mechanism of DKK1 should be further investigated in the HCC cell line or HCC mouse model. Second, our data confirmed that DKK1 activates downstream molecules of VEGFR2 signaling, but further studies are required to determine the underlying mechanism. In addition, since DKK1 is known to be a Wnt signaling antagonist, it needs to be a studied whether the activation of VEGFR2 signaling by DKK1 is dependent or independent of Wnt signaling.

In conclusion, our findings demonstrated that DKK1 facilitates endothelial cell angiogenesis through the upregulation of VEGFR2-mediated mTOR/p70S6K signaling and promotes HCC progression through the activation of EMT factors in diverse HCC models. Our results suggest that DKK1 is a potential therapeutic target for HCC.

### Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (no. 2019R1A2C4070136) and by a faculty research grant from Yonsei University College of Medicine (6-2018-0130).

### Disclosure of conflict of interest

None.

Address correspondence to: Dr. Seung Up Kim, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: +82-2-2228-1944; Fax: +82-2-362-6884; E-mail: ksukorea@yuhs.ac

### References

- [1] Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
- [2] Liu K, Min XL, Peng J, Yang K, Yang L and Zhang XM. The changes of HIF-1 $\alpha$  and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res 2016; 8: 297-302.
- [3] Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
- Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003; 54: 17-28.
- [5] Daher S, Massarwa M, Benson AA and Khoury T. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol 2018; 6: 69-78.
- [6] Kong L, Zhang X, Li C and Zhou L. Potential therapeutic targets and small molecular drugs for pediatric B-precursor acute lymphoblastic

leukemia treatment based on microarray data. Oncol Lett 2017; 14: 1543-1549.

- [7] Arciero CA and Sigurdson ER. Liver-directed therapies for hepatocellular carcinoma. J Natl Compr Canc Netw 2006; 4: 768-774.
- [8] Amini A, Masoumi Moghaddam S, Morris DL and Pourgholami MH. The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets 2012; 12: 23-43.
- [9] Yi ZY, Feng LJ, Xiang Z and Yao H. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J Invest Surg 2011; 24: 67-76.
- [10] Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C and Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998; 391: 357-362.
- [11] Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH and Aaronson SA. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999; 274: 19465-19472.
- [12] Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A and Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 2002; 417: 664-667.
- [13] Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A and Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411: 321-325.
- [14] Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, Chen L, Tsukui T, Gomer L, Dorward DW, Glinka A, Grinberg A, Huang SP, Niehrs C, Izpisúa Belmonte JC and Westphal H. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001; 1: 423-434.
- [15] Zorn AM. Wnt signalling: antagonistic Dickkopfs. Curr Biol 2001; 11: R592-595.
- [16] Thompson MD and Monga SP. WNT/betacatenin signaling in liver health and disease. Hepatology 2007; 45: 1298-1305.
- [17] Hu M, Kurobe M, Jeong YJ, Fuerer C, Ghole S, Nusse R and Sylvester KG. Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. Gastroenterology 2007; 133: 1579-1591.
- [18] Choi HJ, Park H, Lee HW and Kwon YG. The Wnt pathway and the roles for its antagonists, DKKS, in angiogenesis. IUBMB Life 2012; 64: 724-731.
- [19] Zhang B and Ma JX. Wnt pathway antagonists and angiogenesis. Protein Cell 2010; 1: 898-906.

- [20] Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL, Li JJ, Luk JM and Ng IO. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011; 31: 1494-1504.
- [21] Kwack MH, Hwang SY, Jang IS, Im SU, Kim JO, Kim MK, Kim JC and Sung YK. Analysis of cellular changes resulting from forced expression of Dickkopf-1 in hepatocellular carcinoma cells. Cancer Res Treat 2007; 39: 30-36.
- [22] Kim SU, Park JH, Kim HS, Lee JM, Lee HG, Kim H, Choi SH, Baek S, Kim BK, Park JY, Kim DY, Ahn SH, Lee JD and Han KH. Serum Dickkopf-1 as a biomarker for the diagnosis of hepatocellular carcinoma. Yonsei Med J 2015; 56: 1296-1306.
- [23] Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H and Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13: 817-826.
- [24] Patil MA, Chua MS, Pan KH, Lin R, Lih CJ, Cheung ST, Ho C, Li R, Fan ST, Cohen SN, Chen X and So S. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 24: 3737-3747.
- [25] Chen L, Li M, Li Q, Wang CJ and Xie SQ. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Mol Cancer 2013; 12: 157.
- [26] Tao YM, Liu Z and Liu HL. Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis 2013; 45: 251-257.
- [27] Choi SH, Kim H, Lee HG, Kim BK, Park JY, Kim DY, Ahn SH, Han KH and Kim SU. Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. Oncotarget 2017; 8: 58974-58984.
- [28] Song Y, Kim SH, Kim KM, Choi EK, Kim J and Seo HR. Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. Sci Rep 2016; 6: 36750.
- [29] Aden DP, Fogel A, Plotkin S, Damjanov I and Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-616.
- [30] Knowles BB, Howe CC and Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.
- [31] Tahergorabi Z and Khazaei M. A review on angiogenesis and its assays. Iran J Basic Med Sci 2012; 15: 1110-1126.

- [32] Ju HL, Ahn SH, Kim DY, Baek S, Chung SI, Seong J, Han KH and Ro SW. Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. PLoS One 2013; 8: e59869.
- [33] Yang Y, Xu J, Ge S and Lai L. CRISPR/Cas: advances, limitations, and applications for precision cancer research. Front Med (Lausanne) 2021; 8: 649896.
- [34] Alyami MZ, Alsaiari SK, Li Y, Qutub SS, Aleisa FA, Sougrat R, Merzaban JS and Khashab NM. Cell-type-specific CRISPR/Cas9 delivery by biomimetic metal organic frameworks. J Am Chem Soc 2020; 142: 1715-1720.
- [35] Smadja DM, d'Audigier C, Weiswald LB, Badoual C, Dangles-Marie V, Mauge L, Evrard S, Laurendeau I, Lallemand F, Germain S, Grelac F, Dizier B, Vidaud M, Bièche I and Gaussem P. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler Thromb Vasc Biol 2010; 30: 2544-2552.
- [36] Weng LH, Ko JY, Wang CJ, Sun YC and Wang FS. Dkk-1 promotes angiogenic responses and cartilage matrix proteinase secretion in synovial fibroblasts from osteoarthritic joints. Arthritis Rheum 2012; 64: 3267-3277.
- [37] Jiang SJ, Li W, Li YJ, Fang W and Long X. Dickkopf-related protein 1 induces angiogenesis by upregulating vascular endothelial growth factor in the synovial fibroblasts of patients with temporomandibular joint disorders. Mol Med Rep 2015; 12: 4959-4966.
- [38] Matter MS, Decaens T, Andersen JB and Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014; 60: 855-865.
- [39] Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY and van Dam PA. The VEGF pathway and the AKT/mTOR/ p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009; 100: 971-978.
- [40] Li W, Tan D, Zhang Z, Liang JJ and Brown RE. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 2008; 20: 713-719.
- [41] Wang C, Cigliano A, Jiang L, Li X, Fan B, Pilo MG, Liu Y, Gui B, Sini M, Smith JW, Dombrowski F, Calvisi DF, Evert M and Chen X. 4EBP1/ eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology 2015; 61: 200-213.
- [42] Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mam-

malian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66: 2028-2037.

- [43] Pratheeshkumar P, Budhraja A, Son YO, Wang X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, Chen G, Luo J and Shi X. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/ mTOR/P70S6K signaling pathways. PLoS One 2012; 7: e47516.
- [44] Sodek KL, Ringuette MJ and Brown TJ. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009; 124: 2060-2070.
- [45] Cho K, Ro SW, Lee HW, Moon H, Han S, Kim HR, Ahn SH, Park JY and Kim DY. YAP/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation. Hepatology 2021.
- [46] Piccolo S, Dupont S and Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014; 94: 1287-1312.
- [47] Jorgenson AJ, Choi KM, Sicard D, Smith KM, Hiemer SE, Varelas X and Tschumperlin DJ. TAZ activation drives fibroblast spheroid growth, expression of profibrotic paracrine signals, and context-dependent ECM gene expression. Am J Physiol Cell Physiol 2017; 312: C277-C285.
- [48] Kelm JM, Timmins NE, Brown CJ, Fussenegger M and Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003; 83: 173-180.
- [49] Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, Ruff LE and Skubitz AP. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001; 159: 2071-2080.
- [50] Yao L, Zhang D, Zhao X, Sun B, Liu Y, Gu Q, Zhang Y, Zhao X, Che N, Zheng Y, Liu F, Wang Y and Meng J. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype. J Cell Mol Med 2016; 20: 1673-1685.

- [51] Fezza M, Moussa M, Aoun R, Haber R and Hilal G. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1. PLoS One 2019; 14: e0223252.
- [52] Giannelli G, Koudelkova P, Dituri F and Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol 2016; 65: 798-808.
- [53] Cheng SL, Shao JS, Behrmann A, Krchma K and Towler DA. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 1679-1689.
- [54] DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S and Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69: 5364-5373.
- [55] Mitra A, Menezes ME, Shevde LA and Samant RS. DNAJB6 induces degradation of betacatenin and causes partial reversal of mesenchymal phenotype. J Biol Chem 2010; 285: 24686-24694.
- [56] Menezes ME, Devine DJ, Shevde LA and Samant RS. Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer 2012; 130: 1477-1483.
- [57] Potenta S, Zeisberg E and Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008; 99: 1375-1379.
- [58] Thompson EW, Newgreen DF and Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5995; discussion 5995.